



(86) Date de dépôt PCT/PCT Filing Date: 2007/11/20
(87) Date publication PCT/PCT Publication Date: 2008/08/21
(45) Date de délivrance/Issue Date: 2015/02/10
(85) Entrée phase nationale/National Entry: 2009/05/28
(86) N° demande PCT/PCT Application No.: US 2007/085164
(87) N° publication PCT/PCT Publication No.: 2008/100353
(30) Priorités/Priorities: 2006/11/29 (US60/861,455);
2006/12/01 (US60/872,200); 2007/09/14 (US60/972,502)

(51) Cl.Int./Int.Cl. *C12N 15/82* (2006.01),
A01H 1/00 (2006.01), *A01H 5/00* (2006.01),
C12N 9/10 (2006.01)

(72) Inventeurs/Inventors:
SCHOUTEN, LAURA COOPER, US;
PETERS, CHERYL L., US;
VANDE BERG, BRIAN, US;
HINSON, TODD, US;
BELINSON, VADIM, US

(73) Propriétaire/Owner:
ATHENIX CORPORATION, US

(74) Agent: SMART & BIGGAR

(54) Titre : GRG23 EPSP SYNTHASES AMELIOREES : COMPOSITIONS ET PROCEDES D'UTILISATION
(54) Title: IMPROVED GRG23 EPSP SYNTHASES: COMPOSITIONS AND METHODS OF USE

(57) **Abrégé/Abstract:**

Compositions and methods for conferring herbicide resistance or tolerance to bacteria, plants, plant cells, tissues and seeds are provided. Compositions include polynucleotides encoding herbicide resistance or tolerance polypeptides, vectors comprising those polynucleotides, and host cells comprising the vectors. The nucleotide sequences of the invention can be used in DNA constructs or expression cassettes for transformation and expression in organisms, including microorganisms and plants. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated polynucleotides encoding glyphosate resistance or tolerance polypeptides are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated polynucleotides containing nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, or the nucleotide sequence set forth in SEQ ID NO:6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2008 (21.08.2008)

PCT

(10) International Publication Number
WO 2008/100353 A3

(51) International Patent Classification:

C12N 15/82 (2006.01) *A01H 5/00* (2006.01)

C12N 9/10 (2006.01) *A01H 1/00* (2006.01)

(21) International Application Number:

PCT/US2007/085164

(22) International Filing Date:

20 November 2007 (20.11.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/861,455 29 November 2006 (29.11.2006) US

60/872,200 1 December 2006 (01.12.2006) US

60/972,502 14 September 2007 (14.09.2007) US

(71) Applicant (for all designated States except US):

ATHENIX CORPORATION [US/US]; 108 T.W. Alexander Drive, PO Box 110347, Research Triangle Park, NC 27709 (US).

(72) Inventors; and

(75) **Inventors/Applicants (for US only): SCHOUTEN, Laura, Cooper** [US/US]; 3011 Grande Valley Circle, Cary, NC 27513 (US). **PETERS, Cheryl** [US/US]; 6308 Valley Estates Drive, Raleigh, NC 27612 (US). **VANDE BERG, Brian** [US/US]; 5012 Silhouette Drive, Durham, NC 27713 (US). **HINSON, Todd** [US/US]; 3510 Moriah Road, Rougement, NC 27572 (US).

(74) **Agents: BALTICH, Dane et al.**; Alston & Bird LLP, Bank Of America Plaza, 101 South Tryon Street, Suite 4000, Charlotte, NC 28280-4000 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:

6 November 2008

(54) **Title:** IMPROVED GRG23 EPSP SYNTHASES: COMPOSITIONS AND METHODS OF USE

(57) **Abstract:** Compositions and methods for conferring herbicide resistance or tolerance to bacteria, plants, plant cells, tissues and seeds are provided. Compositions include polynucleotides encoding herbicide resistance or tolerance polypeptides, vectors comprising those polynucleotides, and host cells comprising the vectors. The nucleotide sequences of the invention can be used in DNA constructs or expression cassettes for transformation and expression in organisms, including microorganisms and plants. Compositions also include transformed bacteria, plants, plant cells, tissues, and seeds.. In particular, isolated polynucleotides encoding glyphosate resistance or tolerance polypeptides are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated polynucleotides containing nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, or the nucleotide sequence set forth in SEQ ID NO:6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34.



WO 2008/100353 A3

IMPROVED GRG23 EPSP SYNTHASES: COMPOSITIONS AND METHODS OF USE

FIELD OF THE INVENTION

This invention relates to plant molecular biology, particularly novel EPSP synthase polypeptides that confer improved resistance or tolerance to the herbicide glyphosate.

5

BACKGROUND OF THE INVENTION

N-phosphonomethylglycine, commonly referred to as glyphosate, is an important agronomic chemical. Glyphosate inhibits the enzyme that converts phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid (S3P) to 5-enolpyruvyl-
10 3-phosphoshikimic acid. Inhibition of this enzyme (5-enolpyruvylshikimate-3-phosphate synthase; referred to herein as “EPSP synthase”, or “EPSPS”) kills plant cells by shutting down the shikimate pathway, thereby inhibiting aromatic amino acid biosynthesis.

Since glyphosate-class herbicides inhibit aromatic amino acid biosynthesis,
15 they not only kill plant cells, but are also toxic to bacterial cells. Glyphosate inhibits many bacterial EPSP synthases, and thus is toxic to these bacteria. However, certain bacterial EPSP synthases have a high tolerance to glyphosate.

Plant cells resistant to glyphosate toxicity can be produced by transforming plant cells to express glyphosate-resistant bacterial EPSP synthases. Notably, the
20 bacterial gene from *Agrobacterium tumefaciens* strain CP4 has been used to confer herbicide resistance on plant cells following expression in plants. A mutated EPSP synthase from *Salmonella typhimurium* strain CT7 confers glyphosate resistance in bacterial cells, and confers glyphosate resistance on plant cells (U.S. Patent Nos. 4,535,060; 4,769,061; and 5,094,945).

25 U.S. patent 6,040,497 reports mutant maize EPSP synthase enzymes having substitutions of threonine to isoleucine at position 102 and proline to serine at position

106 (the “TIPS” mutation). Such alterations confer glyphosate resistance upon the maize enzyme. A mutated EPSP synthase from *Salmonella typhimurium* strain CT7 confers glyphosate resistance in bacterial cells, and is reported to confer glyphosate resistance upon plant cells (U.S. Patent Nos. 4,535,060; 4,769,061; and 5,094,945).

5 He *et al.* ((2001) *Biochim et Biophysica Acta* 1568:1-6) have developed EPSP synthases with increased glyphosate tolerance by mutagenesis and recombination between the *E. coli* and *Salmonella typhimurium* EPSP synthase genes, and suggest that mutations at position 42 (T42M) and position 230 (Q230K) are likely responsible for the observed resistance. Subsequent work (He *et al.* (2003) *Biosci. Biotech. Biochem.* 67:1405-1409) shows that the T42M mutation (threonine to methionine) is sufficient to improve tolerance of both the *E. coli* and *Salmonella typhimurium* enzymes. Due to the many advantages herbicide resistance plants provide, herbicide resistance genes improved glyphosate resistance activity are desirable.

An alternate method for mutagenesis is the “permutational mutagenesis”
15 method described in U.S. Patent Application No. 60/813,095, filed June 13, 2006.

SUMMARY OF INVENTION

Compositions and methods for conferring resistance or tolerance to are provided. Compositions include EPSP synthase enzymes that are resistant to
20 glyphosate herbicide, and nucleic acid molecules encoding such enzymes, vectors comprising those nucleic acid molecules, and host cells comprising the vectors. The compositions include nucleic acid molecules encoding herbicide resistance polypeptides, including those encoding polypeptides comprising SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, as well as the polynucleotide
25 sequences of SEQ ID NO:6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in organisms, including microorganisms and plants. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds that are glyphosate resistant by the introduction of the compositions of the
30 invention into the genome of the organism. Where the organism is a plant, the introduction of the sequence allows for glyphosate containing herbicides to be applied to plants to selectively kill glyphosate sensitive weeds or other untransformed plants, but not the transformed organism. The sequences can additionally be used a marker for selection of plant cells growing under glyphosate conditions.

53645-19

Methods for identifying an EPSP synthase enzyme with glyphosate resistance activity are additionally provided. The methods comprise identifying additional EPSP synthase sequences that are resistant to glyphosate based on the presence of the domain of the invention.

The invention relates to the following aspects:

- 5 - an isolated or recombinant nucleic acid molecule selected from the group consisting of: a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34; and, b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35;
- a vector comprising the nucleic acid molecule as described herein;
- 10 - a bacterial host cell comprising the nucleic acid molecule as described herein;
- a plant host cell comprising the nucleic acid molecule as described herein;
- a method for obtaining a transformed plant cell, characterized in that it comprises: a) transforming a plant cell with the vector as described herein; b) culturing said plant cell under plant cell growing conditions;
- 15 - an isolated or recombinant polypeptide selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35; and, b) a polypeptide encoded by the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34;
- a method for producing a polypeptide with herbicide resistance activity, comprising culturing the plant host cell as described herein under conditions in which a nucleic acid molecule
- 20 encoding the polypeptide is expressed, said polypeptide being selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35; and, b) a polypeptide encoded by the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34;
- a method for conferring resistance to an herbicide in a plant, said method comprising transforming said plant with a DNA construct, said construct comprising a promoter that drives
- 25 expression in a plant cell operably linked with a nucleotide sequence selected from the group consisting of SEQ ID NO:28, 30, 32, or 34, and regenerating a transformed plant;

53645-19

- a method for obtaining a transformed plant, characterized in that it comprises the steps of: a) transforming a plant cell with a DNA construct comprising a nucleotide sequence that encodes a protein having herbicide resistance activity, wherein said nucleotide sequence is selected from the group consisting of: i) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34; and, ii) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35; wherein said nucleotide sequence is operably linked to a promoter that drives expression of a coding sequence in a plant cell; b) culturing said plant cell under plant cell growing conditions; and c) regenerating a transformed plant.

- a plant cell having stably incorporated into its genome a DNA construct comprising a nucleotide sequence that encodes a protein having herbicide resistance activity, wherein said nucleotide sequence is selected from the group consisting of: a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:28, 30, 32 or 34; and, b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35; wherein said nucleotide sequence is operably linked to a promoter that drives expression of a coding sequence in a plant cell.

- a method for increasing vigor or yield in a plant comprising: a) providing a plant comprising the nucleotide sequence set forth in SEQ ID NO:28, 30, 32, or 34; b) contacting said plant with an effective concentration of glyphosate; and, c) growing said plant under conditions wherein the temperature is higher than ambient environmental temperature for at least two consecutive hours per day for at least four days following contact with said glyphosate, wherein said days following contact is within the growing season of the plant, wherein the vigor or yield of said plant is higher than the vigor or yield of a plant expressing a glyphosate tolerance EPSP synthase that does not have a temperature optimum higher than ambient environmental temperature; and

- a method for conferring resistance to glyphosate in a plant comprising: a) providing a plant comprising the nucleotide sequence set forth in SEQ ID NO:28, 30, 32, or 34; b) contacting said plant with an effective concentration of glyphosate; and, c) growing said plant under conditions wherein the temperature is higher than ambient environmental temperature for at least two consecutive hours per day for at least four days following contact with said glyphosate, wherein said days following contact is within the growing season of the plant.

53645-19

DESCRIPTION OF FIGURES

Figure 1 demonstrates the enzymatic activity of GRG23(ace1) ("M5"; SEQ ID NO:10) compared to wild type GRG23 ("WTGRG23"; SEQ ID NO:2) at 37°C for 0 to 25 hours .

5 Figure 2 shows the resistance of GRG23 and several variants to glyphosate, expressed as the inhibition constant, or K_i

Figure 3 shows the half life of GRG23 and GRG23 variants at 37°C.

DETAILED DESCRIPTION OF THE INVENTION

10 The present inventions now will be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all embodiments of the inventions are shown. Indeed, these inventions may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy
15 applicable legal requirements. Like numbers refer to like elements throughout.

Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to
20 the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

The present invention is drawn to compositions and methods for regulating
25 herbicide resistance in organisms, particularly in plants or plant cells. The methods involve transforming organisms with nucleotide sequences encoding the glyphosate resistance gene of the invention. The nucleotide sequences of the invention are useful for preparing plants that show increased tolerance to the herbicide glyphosate. Thus, by "glyphosate resistance" or "glyphosate tolerance" gene of the invention is intended

the nucleotide sequence set forth in SEQ ID NO:6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34, and fragments and variants thereof that encode a glyphosate resistance or tolerance polypeptide. Likewise, a “glyphosate resistance” or “glyphosate tolerance” polypeptide of the invention is a polypeptide having the amino acid sequence set forth in SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, and fragments and variants thereof, that confer glyphosate resistance or tolerance to a host cell.

A. Isolated polynucleotides, and variants and fragments thereof

In some embodiments, the present invention comprises isolated, recombinant, or purified polynucleotides. An “isolated” or “purified” polynucleotide or polypeptide, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. By “biologically active” is intended to possess the desired biological activity of the native polypeptide, that is, retain herbicide resistance activity. An “isolated” polynucleotide may be free of sequences (for example, protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the polynucleotide is derived. For purposes of the invention, “isolated” when used to refer to polynucleotides excludes isolated chromosomes. For example, in various embodiments, the isolated glyphosate resistance-encoding polynucleotide can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequence that naturally flanks the polynucleotide in genomic DNA of the cell from which the polynucleotide is derived.

Polynucleotides of the invention include those that encode glyphosate-resistant polypeptides comprising SEQ ID NO:9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35, as well as the polynucleotide sequences of SEQ ID NO:6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, or 34.

By “glyphosate” is intended any herbicidal form of N-phosphonomethylglycine (including any salt thereof) and other forms that result in the production of the glyphosate anion *in planta*. An “herbicide resistance protein” or a protein resulting from expression of an “herbicide resistance-encoding nucleic acid molecule” includes proteins that confer upon a cell the ability to tolerate a higher

53645-19

concentration of an herbicide than cells that do not express the protein, or to tolerate a certain concentration of an herbicide for a longer time than cells that do not express the protein. A "glyphosate resistance protein" includes a protein that confers upon a cell the ability to tolerate a higher concentration of glyphosate than cells that do not express the protein, or to tolerate a certain concentration of glyphosate for a longer period of time than cells that do not express the protein. By "tolerate" or "tolerance" is intended either to survive, or to carry out essential cellular functions such as protein synthesis and respiration in a manner that is not readily discernable from untreated cells.

The present invention further contemplates variants and fragments of the polynucleotides described herein. A "fragment" of a polynucleotide may encode a biologically active portion of a polypeptide, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed elsewhere herein. Polynucleotides that are fragments of a polynucleotide comprise at least about 15, 20, 50, 75, 100, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950 contiguous nucleotides, or up to the number of nucleotides present in a full-length polynucleotide disclosed herein depending upon the intended use (e.g., an EPSP synthase polynucleotide comprising SEQ ID NO:1). By "contiguous" nucleotides is intended nucleotide residues that are immediately adjacent to one another.

Fragments of the polynucleotides of the present invention generally will encode polypeptide fragments that retain the biological activity of the full-length glyphosate resistance protein; i.e., herbicide-resistance activity. By "retains herbicide resistance activity" is intended that the fragment will have at least about 30%, at least about 50%, at least about 70%, at least about 80%, 85%, 90%, 95%, 100%, 110%, 125%, 150%, 175%, 200%, 250%, at least about 300% or greater of the herbicide resistance activity of the full-length glyphosate resistance protein disclosed herein as SEQ ID NO:2, 3, or 5. Methods for measuring herbicide resistance activity are well known in the art. See, for example, U.S. Patent Nos. 4,535,060, and 5,188,642.

A fragment of a polynucleotide that encodes a biologically active portion of a polypeptide of the invention will encode at least about 15, 25, 30, 50, 75, 100, 125,

150, 175, 200, 250, 300, 350, 400 contiguous amino acids, or up to the total number of amino acids present in a full-length polypeptide of the invention.

The invention also encompasses variant polynucleotides. “Variants” of the polynucleotide include those sequences that encode the polypeptides disclosed herein
5 but that differ conservatively because of the degeneracy of the genetic code, as well as those that are sufficiently identical.

The term “sufficiently identical” is intended a polypeptide or polynucleotide sequence that has at least about 60% or 65% sequence identity, about 70% or 75% sequence identity, about 80% or 85% sequence identity, about 90%, 91%, 92%, 93%,
10 94%, 95%, 96%, 97%, 98% or 99% sequence identity compared to a reference sequence using one of the alignment programs using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of polypeptides encoded by two polynucleotides by taking into account codon degeneracy, amino acid similarity, reading frame
15 positioning, and the like.

Bacterial genes quite often possess multiple methionine initiation codons in proximity to the start of the open reading frame. Often, translation initiation at one or more of these start codons will lead to generation of a functional protein. These start codons can include ATG codons. However, bacteria such as *Bacillus* sp. also
20 recognize the codon GTG as a start codon, and proteins that initiate translation at GTG codons contain a methionine at the first amino acid. Furthermore, it is not often determined *a priori* which of these codons are used naturally in the bacterium. Thus, it is understood that use of one of the alternate methionine codons may lead to generation of variants that confer herbicide resistance. These herbicide resistance
25 proteins are encompassed in the present invention and may be used in the methods of the present invention.

Naturally occurring allelic variants can be identified with the use of well-known molecular biology techniques, such as polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant polynucleotides also include
30 synthetically derived polynucleotides that have been generated, for example, by using site-directed or other mutagenesis strategies but which still encode the polypeptide having the desired biological activity.

The skilled artisan will further appreciate that changes can be introduced by further mutation of the polynucleotides of the invention thereby leading to further

53645-19

changes in the amino acid sequence of the encoded polypeptides, without altering the biological activity of the polypeptides. Thus, variant isolated polynucleotides can be created by introducing one or more additional nucleotide substitutions, additions, or deletions into the corresponding polynucleotide encoding the EPSP synthase domain
 5 disclosed herein, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded polypeptide. Further mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis, or gene shuffling techniques. Such variant polynucleotides are also encompassed by the present invention.

10 Variant polynucleotides can be made by introducing mutations randomly along all or part of the coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for the ability to confer herbicide resistance activity to identify mutants that retain activity.

Gene shuffling or sexual PCR procedures (for example, Smith (1994) *Nature*
 15 370:324-325; U.S. Pat. Nos. 5,837,458; 5,830,721; 5,811,238; and 5,733,731) can be used to further modify or enhance polynucleotides and polypeptides having the EPSP synthase domain of the present invention (for example, polypeptides that confer glyphosate resistance). Gene shuffling involves random fragmentation of several mutant DNAs followed by their
 20 reassembly by PCR into full length molecules. Examples of various gene shuffling procedures include, but are not limited to, assembly following DNase treatment, the staggered extension process (STEP), and random priming *in vitro* recombination. In the DNase mediated method, DNA segments isolated from a pool of positive mutants are cleaved into random fragments with DNaseI and subjected to multiple rounds of
 25 PCR with no added primer. The lengths of random fragments approach that of the uncleaved segment as the PCR cycles proceed, resulting in mutations in different clones becoming mixed and accumulating in some of the resulting sequences. Multiple cycles of selection and shuffling have led to the functional enhancement of several enzymes (Stemmer (1994) *Nature* 370:389-391; Stemmer (1994) *Proc. Natl. Acad. Sci. USA* 91:10747-10751; Cramer *et al.* (1996) *Nat. Biotechnol.* 14:315-319;
 30 Zhang *et al.* (1997) *Proc. Natl. Acad. Sci. USA* 94:4504-4509; and Cramer *et al.* (1997) *Nat. Biotechnol.* 15:436-438). Such procedures could be performed, for example, on polynucleotides encoding polypeptides having the sequence domain of the present invention to generate polypeptides that confer glyphosate resistance.

Using methods such as PCR, hybridization, and the like corresponding herbicide resistance sequences can be identified by looking for EPSP synthase domains of the present invention. See, for example, Sambrook and Russell (2001) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) and Innis *et al.* (1990) *PCR Protocols: A Guide to Methods and Applications* (Academic Press, NY).

B. Isolated Proteins and Variants and Fragments Thereof

Herbicide resistance polypeptides are also encompassed within the present invention. An herbicide resistance polypeptide that is substantially free of cellular material includes preparations of polypeptides having less than about 30%, 20%, 10%, or 5% (by dry weight) of non-herbicide resistance polypeptide (also referred to herein as a “contaminating protein”). In the present invention, “herbicide resistance protein” is intended an EPSP synthase polypeptide having the sequence domain of the invention. Fragments, biologically active portions, and variants thereof are also provided, and may be used to practice the methods of the present invention.

“Fragments” or “biologically active portions” include polypeptide fragments comprising a portion of an amino acid sequence encoding an herbicide resistance protein and that retains herbicide resistance activity. A biologically active portion of an herbicide resistance protein can be a polypeptide that is, for example, 10, 25, 50, 100 or more amino acids in length. Such biologically active portions can be prepared by recombinant techniques and evaluated for herbicide resistance activity.

By “variants” is intended proteins or polypeptides having an amino acid sequence that is at least about 60%, 65%, about 70%, 75%, about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an EPSP synthase polypeptide having the EPSP synthase domain of the present invention. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of polypeptides encoded by two polynucleotides by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like.

For example, conservative amino acid substitutions may be made at one or more nonessential amino acid residues. A “nonessential” amino acid residue is a residue that can be altered from the wild-type sequence of a polypeptide without altering the biological activity, whereas an “essential” amino acid residue is required

for biological activity. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Amino acid substitutions may be made in nonconserved regions that retain function. In general, such substitutions would not be made for conserved amino acid residues, or for amino acid residues residing within a conserved motif, where such residues are essential for polypeptide activity. However, one of skill in the art would understand that functional variants may have minor conserved or nonconserved alterations in the conserved residues.

Antibodies to the polypeptides of the present invention, or to variants or fragments thereof, are also encompassed. Methods for producing antibodies are well known in the art (see, for example, Harlow and Lane (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; U.S. Patent No. 4,196,265).

C. Polynucleotide Constructs

The polynucleotides encoding the EPSP synthase polypeptides of the present invention may be modified to obtain or enhance expression in plant cells. The polynucleotides encoding the polypeptides identified herein may be provided in expression cassettes for expression in the plant of interest. A “plant expression cassette” includes a DNA construct, including a recombinant DNA construct, that is capable of resulting in the expression of a polynucleotide in a plant cell. The cassette can include in the 5'-3' direction of transcription, a transcriptional initiation region (i.e., promoter, particularly a heterologous promoter) operably-linked to one or more polynucleotides of interest, and/or a translation and transcriptional termination region (i.e., termination region) functional in plants. The cassette may additionally contain at least one additional polynucleotide to be introduced into the organism, such as a selectable marker gene. Alternatively, the additional polynucleotide(s) can be

provided on multiple expression cassettes. Such an expression cassette is provided with a plurality of restriction sites for insertion of the polynucleotide(s) to be under the transcriptional regulation of the regulatory regions.

“Heterologous” generally refers to the polynucleotide or polypeptide that is not endogenous to the cell or is not endogenous to the location in the native genome in which it is present, and has been added to the cell by infection, transfection, microinjection, electroporation, microprojection, or the like. By “operably linked” is intended a functional linkage between two polynucleotides. For example, when a promoter is operably linked to a DNA sequence, the promoter sequence initiates and mediates transcription of the DNA sequence. It is recognized that operably linked polynucleotides may or may not be contiguous and, where used to reference the joining of two polypeptide coding regions, the polypeptides are expressed in the same reading frame.

The promoter may be any polynucleotide sequence which shows transcriptional activity in the chosen plant cells, plant parts, or plants. The promoter may be native or analogous, or foreign or heterologous, to the plant host and/or to the DNA sequence of the invention. Where the promoter is “native” or “analogous” to the plant host, it is intended that the promoter is found in the native plant into which the promoter is introduced. Where the promoter is “foreign” or “heterologous” to the DNA sequence of the invention, it is intended that the promoter is not the native or naturally occurring promoter for the operably linked DNA sequence of the invention. The promoter may be inducible or constitutive. It may be naturally-occurring, may be composed of portions of various naturally-occurring promoters, or may be partially or totally synthetic. Guidance for the design of promoters is provided by studies of promoter structure, such as that of Harley and Reynolds (1987) *Nucleic Acids Res.* 15:2343-2361. Also, the location of the promoter relative to the transcription start may be optimized. See, e.g., Roberts *et al.* (1979) *Proc. Natl. Acad. Sci. USA*, 76:760-764. Many suitable promoters for use in plants are well known in the art.

For instance, suitable constitutive promoters for use in plants include: the promoters from plant viruses, such as the peanut chlorotic streak caulimovirus (PClSV) promoter (U.S. Pat. No. 5,850,019); the 35S promoter from cauliflower mosaic virus (CaMV) (Odell *et al.* (1985) *Nature* 313:810-812); promoters of *Chlorella* virus methyltransferase genes (U.S. Pat. No. 5,563,328) and the full-length transcript promoter from figwort mosaic virus (FMV) (U.S. Pat. No. 5,378,619); the

53645-19

promoters from such genes as rice actin (McElroy *et al.* (1990) *Plant Cell* 2:163-171); ubiquitin (Christensen *et al.* (1989) *Plant Mol. Biol.* 12:619-632 and Christensen *et al.* (1992) *Plant Mol. Biol.* 18:675-689); pEMU (Last *et al.* (1991) *Theor. Appl. Genet.* 81:581-588); MAS (Velten *et al.* (1984) *EMBO J.* 3:2723-2730); maize H3 histone
 5 (Lepetit *et al.* (1992) *Mol. Gen. Genet.* 231:276-285 and Atanassova *et al.* (1992) *Plant J.* 2(3):291-300); Brassica napus ALS3 (PCT application WO 97/41228); and promoters of various *Agrobacterium* genes (see U.S. Pat. Nos. 4,771,002; 5,102,796; 5,182,200; and 5,428,147).

Suitable inducible promoters for use in plants include: the promoter from the
 10 ACE1 system which responds to copper (Mett *et al.* (1993) *PNAS* 90:4567-4571); the promoter of the maize In2 gene which responds to benzenesulfonamide herbicide safeners (Hershey *et al.* (1991) *Mol. Gen. Genetics* 227:229-237 and Gatz *et al.* (1994) *Mol. Gen. Genetics* 243:32-38); and the promoter of the Tet repressor from Tn10 (Gatz *et al.* (1991) *Mol. Gen. Genet.* 227:229-237). Another inducible promoter
 15 for use in plants is one that responds to an inducing agent to which plants do not normally respond. An exemplary inducible promoter of this type is the inducible promoter from a steroid hormone gene, the transcriptional activity of which is induced by a glucocorticosteroid hormone (Schena *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:10421) or the recent application of a chimeric transcription activator, XVE, for use
 20 in an estrogen receptor-based inducible plant expression system activated by estradiol (Zuo *et al.* (2000) *Plant J.*, 24:265-273). Other inducible promoters for use in plants are described in EP 332104, PCT WO 93/21334 and PCT WO 97/06269.

Promoters composed of portions of other promoters and partially or totally synthetic promoters can also be used. See, e.g.,
 25 Ni *et al.* (1995) *Plant J.* 7:661-676 and PCT WO 95/14098 describing such promoters for use in plants.

The promoter may include, or be modified to include, one or more enhancer elements. In some embodiments, the promoter may include a plurality of enhancer elements. Promoters containing enhancer elements provide for higher levels of
 30 transcription as compared to promoters that do not include them. Suitable enhancer elements for use in plants include the PCISV enhancer element (U.S. Pat. No. 5,850,019), the CaMV 35S enhancer element (U.S. Pat. Nos. 5,106,739 and 5,164,316) and the FMV enhancer element (Maiti *et al.* (1997) *Transgenic Res.* 6:143-156). See also PCT WO 96/23898.

Often, such constructs can contain 5' and 3' untranslated regions. Such constructs may contain a "signal sequence" or "leader sequence" to facilitate co-translational or post-translational transport of the peptide of interest to certain intracellular structures such as the chloroplast (or other plastid), endoplasmic reticulum, or Golgi apparatus, or to be secreted. For example, the construct can be engineered to contain a signal peptide to facilitate transfer of the peptide to the endoplasmic reticulum. By "signal sequence" is intended a sequence that is known or suspected to result in cotranslational or post-translational peptide transport across the cell membrane. In eukaryotes, this typically involves secretion into the Golgi apparatus, with some resulting glycosylation. By "leader sequence" is intended any sequence that, when translated, results in an amino acid sequence sufficient to trigger co-translational transport of the peptide chain to a sub-cellular organelle. Thus, this includes leader sequences targeting transport and/or glycosylation by passage into the endoplasmic reticulum, passage to vacuoles, plastids including chloroplasts, mitochondria, and the like. It may also be preferable to engineer the plant expression cassette to contain an intron, such that mRNA processing of the intron is required for expression.

By "3' untranslated region" is intended a polynucleotide located downstream of a coding sequence. Polyadenylation signal sequences and other sequences encoding regulatory signals capable of affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor are 3' untranslated regions. By "5' untranslated region" is intended a polynucleotide located upstream of a coding sequence.

Other upstream or downstream untranslated elements include enhancers. Enhancers are polynucleotides that act to increase the expression of a promoter region. Enhancers are well known in the art and include, but are not limited to, the SV40 enhancer region and the 35S enhancer element.

The termination region may be native with the transcriptional initiation region, may be native with the sequence of the present invention, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of *A. tumefaciens*, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau *et al.* (1991) *Mol. Gen. Genet.* 262:141-144; Proudfoot (1991) *Cell* 64:671-674; Sanfacon *et al.* (1991) *Genes Dev.* 5:141-149; Mogen *et al.* (1990) *Plant Cell* 2:1261-1272; Munroe *et al.* (1990) *Gene* 91:151-158; Ballas *et al.*

53645-19

(1989) *Nucleic Acids Res.* 17:7891-7903; and Joshi *et al.* (1987) *Nucleic Acid Res.* 15:9627-9639.

In one aspect of the invention, synthetic DNA sequences are designed for a given polypeptide, such as the polypeptides of the invention. Expression of the open
 5 reading frame of the synthetic DNA sequence in a cell results in production of the polypeptide of the invention. Synthetic DNA sequences can be useful to simply remove unwanted restriction endonuclease sites, to facilitate DNA cloning strategies, to alter or remove any potential codon bias, to alter or improve GC content, to remove or alter alternate reading frames, and/or to alter or remove intron/exon splice
 10 recognition sites, polyadenylation sites, Shine-Delgarno sequences, unwanted promoter elements and the like that may be present in a native DNA sequence. It is also possible that synthetic DNA sequences may be utilized to introduce other improvements to a DNA sequence, such as introduction of an intron sequence, creation of a DNA sequence that is expressed as a protein fusion to organelle
 15 targeting sequences, such as chloroplast transit peptides, apoplast/vacuolar targeting peptides, or peptide sequences that result in retention of the resulting peptide in the endoplasmic reticulum. Synthetic genes can also be synthesized using host cell-preferred codons for improved expression, or may be synthesized using codons at a host-preferred codon usage frequency. See, for example, Campbell and Gowri (1990)
 20 *Plant Physiol.* 92:1-11; U.S. Patent Nos. 6,320,100; 6,075,185; 5,380,831; and 5,436,391, U.S. Published Application Nos. 20040005600 and 20010003849, and Murray *et al.* (1989) *Nucleic Acids Res.* 17:477-498.

In one embodiment, the polynucleotides of interest are targeted to the chloroplast for expression. In this manner, where the polynucleotide of interest is not
 25 directly inserted into the chloroplast, the expression cassette will additionally contain a polynucleotide encoding a transit peptide to direct the nucleotide of interest to the chloroplasts. Such transit peptides are known in the art. See, for example, Von Heijne *et al.* (1991) *Plant Mol. Biol. Rep.* 9:104-126; Clark *et al.* (1989) *J. Biol. Chem.* 264:17544-17550; Della-Cioppa *et al.* (1987) *Plant Physiol.* 84:965-968;
 30 Romer *et al.* (1993) *Biochem. Biophys. Res. Commun.* 196:1414-1421; and Shah *et al.* (1986) *Science* 233:478-481.

The polynucleotides of interest to be targeted to the chloroplast may be optimized for expression in the chloroplast to account for differences in codon usage between the plant nucleus and this organelle. In this manner, the polynucleotides of

53645-19

interest may be synthesized using chloroplast-preferred codons. See, for example, U.S. Patent No. 5,380,831.

This plant expression cassette can be inserted into a plant transformation vector. By “transformation vector” is intended a DNA molecule that allows for the transformation of a cell. Such a molecule may consist of one or more expression cassettes, and may be organized into more than one vector DNA molecule. For example, binary vectors are plant transformation vectors that utilize two non-contiguous DNA vectors to encode all requisite cis- and trans-acting functions for transformation of plant cells (Hellens and Mullineaux (2000) *Trends in Plant Science* 5:446-451). “Vector” refers to a polynucleotide construct designed for transfer between different host cells. “Expression vector” refers to a vector that has the ability to incorporate, integrate and express heterologous DNA sequences or fragments in a foreign cell.

The plant transformation vector comprises one or more DNA vectors for achieving plant transformation. For example, it is a common practice in the art to utilize plant transformation vectors that comprise more than one contiguous DNA segment. These vectors are often referred to in the art as binary vectors. Binary vectors as well as vectors with helper plasmids are most often used for *Agrobacterium*-mediated transformation, where the size and complexity of DNA segments needed to achieve efficient transformation is quite large, and it is advantageous to separate functions onto separate DNA molecules. Binary vectors typically contain a plasmid vector that contains the cis-acting sequences required for T-DNA transfer (such as left border and right border), a selectable marker that is engineered to be capable of expression in a plant cell, and a “polynucleotide of interest” (a polynucleotide engineered to be capable of expression in a plant cell for which generation of transgenic plants is desired). Also present on this plasmid vector are sequences required for bacterial replication. The cis-acting sequences are arranged in a fashion to allow efficient transfer into plant cells and expression therein. For example, the selectable marker sequence and the sequence of interest are located between the left and right borders. Often a second plasmid vector contains the trans-acting factors that mediate T-DNA transfer from *Agrobacterium* to plant cells. This plasmid often contains the virulence functions (Vir genes) that allow infection of plant cells by *Agrobacterium*, and transfer of DNA by cleavage at border sequences and vir-mediated DNA transfer, as is understood in the art (Hellens and Mullineaux

(2000) *Trends in Plant Science*, 5:446-451). Several types of *Agrobacterium* strains (e.g., LBA4404, GV3101, EHA101, EHA105, etc.) can be used for plant transformation. The second plasmid vector is not necessary for introduction of polynucleotides into plants by other methods such as microprojection, microinjection, electroporation, polyethylene glycol, etc.

D. Plant Transformation

Methods of the invention involve introducing a nucleotide construct into a plant. By “introducing” is intended to present to the plant the nucleotide construct in such a manner that the construct gains access to the interior of a cell of the plant. The methods of the invention do not require that a particular method for introducing a nucleotide construct to a plant is used, only that the nucleotide construct gains access to the interior of at least one cell of the plant. Methods for introducing nucleotide constructs into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods.

In general, plant transformation methods involve transferring heterologous DNA into target plant cells (e.g. immature or mature embryos, suspension cultures, undifferentiated callus, protoplasts, etc.), followed by applying a maximum threshold level of appropriate selection (depending on the selectable marker gene and in this case “glyphosate”) to recover the transformed plant cells from a group of untransformed cell mass. Explants are typically transferred to a fresh supply of the same medium and cultured routinely. Subsequently, the transformed cells are differentiated into shoots after placing on regeneration medium supplemented with a maximum threshold level of selecting agent (e.g. “glyphosate”). The shoots are then transferred to a selective rooting medium for recovering rooted shoot or plantlet. The transgenic plantlet then grow into mature plants and produce fertile seeds (e.g. Hiei *et al.* (1994) *The Plant Journal* 6:271-282; Ishida *et al.* (1996) *Nature Biotechnology* 14:745-750). Explants are typically transferred to a fresh supply of the same medium and cultured routinely. A general description of the techniques and methods for generating transgenic plants are found in Ayres and Park (1994) *Critical Reviews in Plant Science* 13:219-239 and Bommineni and Jauhar (1997) *Maydica* 42:107-120. Since the transformed material contains many cells; both transformed and non-transformed cells are present in any piece of subjected target callus or tissue or group

of cells. The ability to kill non-transformed cells and allow transformed cells to proliferate results in transformed plant cultures. Often, the ability to remove non-transformed cells is a limitation to rapid recovery of transformed plant cells and successful generation of transgenic plants. Molecular and biochemical methods can be used to confirm the presence of the integrated heterologous gene of interest in the genome of transgenic plant.

Generation of transgenic plants may be performed by one of several methods, including, but not limited to, introduction of heterologous DNA by *Agrobacterium* into plant cells (*Agrobacterium*-mediated transformation), bombardment of plant cells with heterologous foreign DNA adhered to particles, and various other non-particle direct-mediated methods (e.g. Hiei *et al.* (1994) *The Plant Journal* 6:271-282; Ishida *et al.* (1996) *Nature Biotechnology* 14:745-750; Ayres and Park (1994) *Critical Reviews in Plant Science* 13:219-239; Bommineni and Jauhar (1997) *Maydica* 42:107-120) to transfer DNA.

Methods for transformation of chloroplasts are known in the art. See, for example, Svab *et al.* (1990) *Proc. Natl. Acad. Sci. USA* 87:8526-8530; Svab and Maliga (1993) *Proc. Natl. Acad. Sci. USA* 90:913-917; Svab and Maliga (1993) *EMBO J.* 12:601-606. The method relies on particle gun delivery of DNA containing a selectable marker and targeting of the DNA to the plastid genome through homologous recombination. Additionally, plastid transformation can be accomplished by transactivation of a silent plastid-borne transgene by tissue-preferred expression of a nuclear-encoded and plastid-directed RNA polymerase. Such a system has been reported in McBride *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:7301-7305.

The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick *et al.* (1986) *Plant Cell Reports* 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the present invention provides transformed seed (also referred to as “transgenic seed”)

having a nucleotide construct of the invention, for example, an expression cassette of the invention, stably incorporated into their genome.

E. Evaluation of Plant Transformation

5 Following introduction of heterologous foreign DNA into plant cells, the transformation or integration of the heterologous gene in the plant genome is confirmed by various methods such as analysis of nucleic acids, proteins and metabolites associated with the integrated gene.

10 PCR analysis is a rapid method to screen transformed cells, tissue or shoots for the presence of incorporated gene at the earlier stage before transplanting into the soil (Sambrook and Russell (2001) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY)). PCR is carried out using oligonucleotide primers specific to the gene of interest or *Agrobacterium* vector background, etc.

15 Plant transformation may be confirmed by Southern blot analysis of genomic DNA (Sambrook and Russell (2001) *supra*). In general, total DNA is extracted from the transformant, digested with appropriate restriction enzymes, fractionated in an agarose gel and transferred to a nitrocellulose or nylon membrane. The membrane or “blot” can then be probed with, for example, radiolabeled ³²P target DNA fragment to
20 confirm the integration of the introduced gene in the plant genome according to standard techniques (Sambrook and Russell, 2001, *supra*).

 In Northern analysis, RNA is isolated from specific tissues of transformant, fractionated in a formaldehyde agarose gel, and blotted onto a nylon filter according to standard procedures that are routinely used in the art (Sambrook and Russell (2001) *supra*).
25 Expression of RNA encoded by *grg* sequences of the invention is then tested by hybridizing the filter to a radioactive probe derived from a GDC by methods known in the art (Sambrook and Russell (2001) *supra*)

 Western blot and biochemical assays and the like may be carried out on the transgenic plants to determine the presence of protein encoded by the herbicide
30 resistance gene by standard procedures (Sambrook and Russell (2001) *supra*) using antibodies that bind to one or more epitopes present on the herbicide resistance protein.

 In one aspect of the invention, the *grg* genes described herein are useful as markers to assess transformation of bacterial or plant cells.

F. Plants and Plant Parts

By “plant” is intended whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds, plant cells, propagules, embryos and progeny of the same. Plant cells can be differentiated or undifferentiated (e.g., callus, suspension culture cells, protoplasts, leaf cells, root cells, phloem cells, pollen). The present invention may be used for introduction of polynucleotides into any plant species, including, but not limited to, monocots and dicots. Examples of plants of interest include, but are not limited to, corn (maize), sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, and oilseed rape, *Brassica* sp., alfalfa, rye, millet, safflower, peanuts, sweet potato, cassava, coffee, coconut, pineapple, citrus trees, cocoa, tea, banana, avocado, fig, guava, mango, olive, papaya, cashew, macadamia, almond, oats, vegetables, ornamentals, and conifers.

Vegetables include, but are not limited to, tomatoes, lettuce, green beans, lima beans, peas, and members of the genus *Curcumis* such as cucumber, cantaloupe, and musk melon. Ornamentals include, but are not limited to, azalea, hydrangea, hibiscus, roses, tulips, daffodils, petunias, carnation, poinsettia, and chrysanthemum. Crop plants are also of interest, including, for example, maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, oilseed rape, etc.

This invention is suitable for any member of the monocot plant family including, but not limited to, maize, rice, barley, oats, wheat, sorghum, rye, sugarcane, pineapple, yams, onion, banana, coconut, and dates.

G. Methods for increasing plant yield

Methods for increasing plant yield are provided. The methods comprise introducing into a plant or plant cell a polynucleotide comprising a *grg* sequence disclosed herein. As defined herein, the “yield” of the plant refers to the quality and/or quantity of biomass produced by the plant. By “biomass” is intended any measured plant product. An increase in biomass production is any improvement in the yield of the measured plant product. Increasing plant yield has several commercial applications. For example, increasing plant leaf biomass may increase the yield of leafy vegetables for human or animal consumption. Additionally, increasing leaf biomass can be used to increase production of plant-derived pharmaceutical or industrial products. An increase in yield can comprise any statistically significant

increase including, but not limited to, at least a 1% increase, at least a 3% increase, at least a 5% increase, at least a 10% increase, at least a 20% increase, at least a 30%, at least a 50%, at least a 70%, at least a 100% or a greater increase.

In specific methods, the plant is treated with an effective concentration of an herbicide, where the herbicide application results in enhanced plant yield. By “effective concentration” is intended the concentration which allows the increased yield in the plant. Such effective concentrations for herbicides of interest are generally known in the art. The herbicide may be applied either pre- or post emergence in accordance with usual techniques for herbicide application to fields comprising crops which have been rendered resistant to the herbicide by heterologous expression of a *grg* gene of the invention.

Methods for conferring herbicide resistance in a plant or plant part are also provided. In such methods, a *grg* polynucleotide disclosed herein is introduced into the plant, wherein expression of the polynucleotide results in glyphosate tolerance or resistance. Plants produced via this method can be treated with an effective concentration of an herbicide and display an increased tolerance to the herbicide. An “effective concentration” of an herbicide in this application is an amount sufficient to slow or stop the growth of plants or plant parts that are not naturally resistant or rendered resistant to the herbicide.

20

H. Methods of controlling weeds in a field

Methods for selectively controlling weeds in a field containing a plant are also provided. In one embodiment, the plant seeds or plants are glyphosate resistant as a result of a *grg* polynucleotide disclosed herein being inserted into the plant seed or plant. In specific methods, the plant is treated with an effective concentration of an herbicide, where the herbicide application results in a selective control of weeds or other untransformed plants. By “effective concentration” is intended the concentration which controls the growth or spread of weeds or other untransformed plants without significantly affecting the glyphosate-resistant plant or plant seed. Such effective concentrations for herbicides of interest are generally known in the art. The herbicide may be applied either pre- or post emergence in accordance with usual techniques for herbicide application to fields comprising plants or plant seeds which have been rendered resistant to the herbicide.

30

I. Temperature spectrum

Several studies of glyphosate metabolism in plants have been carried out, and reveal that glyphosate is not metabolized by plants or is metabolized very slowly. Glyphosate penetrates the cuticle rapidly, and is translocated throughout plants over a
5 considerable period of time (reviewed in Kearney and Kaufman, Eds (1988) *Herbicides; Chemistry, Degradation & Mode of Action* Marcel Dekker, Inc., New York, 3:1-70 and Grossbard and Atkinson, Eds. (1985) *The Herbicide Glyphosate* Butterworths, London, p. 25-34). Thus, it is likely that glyphosate tolerance is
10 necessary over a sustained period of time following glyphosate exposure in agronomically-important plants. Where temperatures frequently exceed 30°C during the growing season, it would be advantageous to employ a glyphosate-tolerance EPSP synthase that maintains activity at elevated temperatures.

In one embodiment of the present invention, the EPSP synthase exhibits thermal stability at a temperature that is higher or lower than ambient environmental
15 temperature. By “thermal stability” is intended that the enzyme is active at a higher or lower temperature than ambient environmental temperature for a longer period of time than an EPSP synthase that is not thermal stable at that temperature. For example, a thermal stable EPSP synthase has enzymatic activity for greater than about
20 1 hour, greater than about 2 hours, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 20, about 25 hours, or longer, at a temperature that is higher or lower than ambient environmental temperature. For the purposes of the present invention, “ambient” environmental temperature is about 30°C. In some embodiments, a higher than ambient temperature is a temperature at or above about 32°C, about 34°C, about
25 37°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, or higher. A lower than ambient temperature is a temperature at or below about 28°C, below about 27°C, about 26°C, about 25°C, about 23°C, about 20°C, about 18°C, about 15°C, about 10°C, at or below about 5°C, or around 0°C. Methods to assay for EPSP synthase activity are discussed in further details elsewhere herein. For the
30 purposes of the present invention, a thermal stable EPSP synthase is considered active when it functions at about 90% to 100%, about 80% to about 90%, about 70% to about 80%, about 60% to about 70% or about 50% to about 60% of the maximum activity level observed at the optimum temperature for that enzyme.

Thus, provided herein are methods and compositions for increasing glyphosate tolerance at temperatures higher than ambient environmental temperatures. In one embodiment, the methods comprise introducing into a plant a nucleotide sequence encoding the glyphosate tolerance EPSP synthase enzyme set forth in SEQ ID NO:8, 10, 14, 28, 30, 32, or 34, and growing the plant at a temperature that is higher than ambient environmental temperature. In specific embodiments, the growing temperature is higher than ambient temperature for an average of at least about 2 hours per day, at least about 3 hours per day, at least about 4 hours per day, at least about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 14, about 16, about 18, about 20, at least about 22 hours per day, or up to about 24 hours a day during the growing season of the plant.

In another embodiment, the method comprises introducing into a plant a nucleotide sequence encoding the glyphosate tolerant EPSP synthase enzyme set forth in SEQ ID NO:8, 10, 14, 28, 30, 32, or 34, contacting the plant with an herbicidally-effective concentration of glyphosate, and growing the plant at a temperature that exceeds ambient environmental temperature for at least 1 hour, at least about 2 hours, at least about 3, at least about 4, or more hours per day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more days after glyphosate is applied to the plant, wherein the days in which the temperature exceeds ambient environmental temperature occur during the growing season of the plant.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL

Example 1. *syngrg23* design and expression

GRG23 (SEQ ID NO:2) is an EPSP synthase that possesses excellent kinetic values for K_m , K_i and V_{max} (U.S. Patent Application No. 60/ 741,166 filed December 1, 2005). A novel gene sequence encoding the GRG23 protein (U.S. Patent Application No. 60/741,166 filed December 1, 2005) was designed and synthesized. The resulting sequence is provided herein as SEQ ID NO:6, and is herein designated “*syngrg23*.” The open reading frame was cloned into the expression vector pRSF1b (Invitrogen) by methods known in the art.

The *syngrg23* gene encoding GRG23 was cloned into a pUC19 vector to create pAX748. PCR primers that flanked *syngrg23* in this vector were used to

amplify *syngrg23* from pAX748 using the Mutazyme II system (Stratagene) to introduce random mutations into the *syngrg23* coding region. The template was diluted 1:50 in the error-prone PCR reaction, and amplification was carried out for 30 cycles. The resulting PCR product was digested with the restriction enzymes *BamH* I and *Sgs* I, gel-purified, and ligated into the vector pRSF1b to create a mutagenized *syngrg23* library.

The mutagenized *syngrg23* libraries were transformed into *E. coli* strain BL21*DE3 star (Invitrogen). Following transformation, individual colonies were plated on 1x M63 medium containing 150 mM glyphosate to select for clones that had retained enzymatic activity and growth tolerance.

Example 2. Screening for glyphosate resistance on plates

Library ligations were transformed into BL21*DE3 competent *E. coli* cells (Invitrogen). The transformations were performed according to the manufacturer's instructions with the following modifications. After incubation for 1 hour at 37°C in SOC medium, the cells were sedimented by centrifugation (5 minutes, 1000 x g, 4°C). The cells were washed with 1 ml M63+, centrifuged again, and the supernatant decanted. The cells were washed a second time with 1 ml M63+ and resuspended in 200 ul M63+.

For selection of mutant GRG23 enzymes conferring glyphosate resistance in *E. coli*, the cells were plated onto M63+ agar medium plates containing 150 mM glyphosate, 0.05 mM IPTG (isopropyl-beta-D-thiogalactopyranoside), and 50 µg/ml kanamycin. M63+ medium contains 100 mM KH₂PO₄, 15 mM (NH₄)₂SO₄, 50 µM CaCl₂, 1 µM FeSO₄, 50 µM MgCl₂, 55 mM glucose, 25 mg/liter L-proline, 10 mg/liter thiamine HCl, sufficient NaOH to adjust the pH to 7.0, and 15 g/liter agar. The plates were incubated for 36 hours at 37°C.

Individual colonies were picked and arrayed into 384-well plates. Two 384-well plates were created in this manner. A third plate of 384 clones was picked from colonies that grown on plates lacking glyphosate.

30

Example 3. Isolation and analysis of glyphosate resistant GRG23 variants

BL21*DE3 cells transformed with mutagenized *syngrg23* and/ or *grg23* variants were identified by growth on glyphosate plates. Extracts of mutagenized

syngrg23 and *grgr23* variants were prepared and assayed for improved enzymatic activity. Colonies identified on glyphosate plates were pinned into 96-well blocks containing LB medium and were grown to an O.D. of about 0.6. IPTG was then added (0.5 mM) and the blocks were incubated overnight at 20°C to induce protein expression. Protein extracts were prepared from the cell pellets using POP culture reagent (Novagen) and Lysonase (Novagen), and the enzymatic activity in the crude lysates was measured after heating the extracts for 30 min at 37°C. Extracts with activity greater than two standard deviations above the mean of a set of extracts containing the appropriate control protein (for example GRG23) were selected for further analysis.

Clones showing increased activity after incubation as crude extracts were grown in 250 mL LB cultures, and protein expression induced with IPTG. Following induction, the mutant GRG23 protein was purified from each culture by affinity chromatography using a cobalt resin (Novagen). The purified proteins were then tested for enzymatic activity following heating for 0, 2, 4, and approximately 16 hours at 37°C.

Example 4. Improved GRG23 variants.

From a DNA library of mutagenized *syngrg23*, several clones with improved activity at 37°C were identified. The DNA sequences of the clones corresponding to these extracts was determined. Table 1 shows the amino acid changes identified in six variants of GRG23 that retained glyphosate resistance: *grg23(L3P1.B20)* (SEQ ID NO:20) encoding the amino acid sequence GRG23(L3P1.B20) (SEQ ID NO:21), *grg23(L3P1.B3)* (SEQ ID NO:22) encoding the amino acid sequence grg23(L3P1B3) (SEQ ID NO:23); GRG23(L3P1.F18) (SEQ ID NO:24) encoding the amino acid sequence GRG23(L3P1.F18) (SEQ ID NO:25); and, *grg23(L3P1.O23)* (SEQ ID NO:26) encoding the amino acid sequence GRG23(L3P1.O23) (SEQ ID NO:27).

53645-19

Table 1. Mutations identified in glyphosate-resistant GRG23 variants

Clone	Amino Acid (AA) in GRG23
L3P1B20	V206→I
L3P1B3	D75→H, E217→K
L3P1F18	T274→I
L3P1O23	R5→H

The clones were grown in 250 mL LB cultures, and protein expression induced isolated as described above. The purified proteins were then tested for enzymatic activity following heating for 0, 2, 4, and approximately 16 hours at 37°C. One of the clones, termed "M5", was found to retain an increased proportion of its enzymatic activity after prolonged incubation at 37°C (Table 2). The DNA sequence of this clones was determined, and the gene is designated herein as *grg23(ace1)* (SEQ ID NO:8). The protein expressed from *grg23(ace1)* is designated GRG23(ACE1) (SEQ ID NO:9).

Table 2. Half-life of GRG23(ACE1) vs GRG23 at elevated temperature

Protein	Half-life at 37°C (hours)
GRG23	7
GRG23(ACE1)	15.5

GRG23(ACE1) contains 2 amino acid substitutions relative to wild-type GRG23 protein: A49→T and S276→T. The pRSF1b vector that contains this gene is designated pAX3801. Figure 1 shows the relative stability of GRG23 (ACE1) vs GRG23 at elevated temperatures.

Example 5. Determination of EPSPS activity of GRG-23 variants

Extracts containing GRG23 variant proteins were assayed for EPSP synthase activity as described in U.S. Patent Application Number 60/741,166 filed December 1, 2005. Assays were carried out in a final volume of 50 ul containing 0.5 mM shikimate-3-phosphate, 200 uM phosphoenolpyruvate (PEP), 1 U/ml xanthine oxidase, 2 U/ml nucleoside phosphorylase, 2.25 mM inosine, 1 U/ml horseradish peroxidase, 2 mM glyphosate,

50 mM HEPES/KOH pH 7.0, 100 mM KCl, and AMPLEX® Red (Invitrogen) according to the manufacturer's instructions. Extracts were incubated with all assay components except shikimate-3-phosphate for 5 minutes at room temperature, and assays were started by adding shikimate-3-phosphate. EPSP synthase activity was measured using a Spectramax Gemini XPS fluorescence spectrometer (Molecular Dynamics, excitation: 555 nm; emission: 590 nm).

A full determination of kinetic parameters was performed on purified protein as previously described (U.S. Patent Application Number 60/ 741,166 filed December 1, 2005), adjusting for the quantity of protein determined by Bradford assay as known in the art. For any one glyphosate concentration, EPSP synthase activity was measured as a function of a broad range of PEP concentrations. The data were fit to the Michaelis-Menten equation using KALEIDAGRAPH® software (Synergy Software) and used to determine the K_m (K_m apparent) of the EPSP synthase at that glyphosate concentration. K_m apparent values were determined at no fewer than four glyphosate concentrations, and the K_i of the EPSPS for glyphosate was calculated from the plot of K_m apparent vs. glyphosate concentration, using the equation ($m1 * x / (m2 + x)$; $m1 = 1$; $m2 = 1$) as known in the art.

Table 3. Kinetics of GRG23(ACE1) vs GRG23

	K_m (μM)	K_i (μM)	V_{max} (nmol/min/ μg)
GRG23	12.2	13,800	14.77
GRG23(ACE1)	9.7	14,620	13.73

Example 6. Identification of *grg23(ace2)*.

GRG23(ACE1) contains two amino acid changes relative to GRG23. To determine if additional substitutions at these positions could further improve activity, a DNA library was generated that resulted in clones expressing proteins that were substantially mutated at positions 49 and 276 corresponding to GRG23 (SEQ ID NO:2). Clones conferring glyphosate resistance were selected by growth on glyphosate plates, and grown and assayed for kinetic properties as described.

Surprisingly, one clone, herein designated *grg23(ace2)* (SEQ ID NO:10), encoding the GRG23(ACE2) protein (SEQ ID NO:11) was identified as having improved thermostability. The DNA sequence of *grg23(ace2)* shows that

GRG23(ACE2) contains a single amino acid change (residue 276 of GRG23 to arginine).

Example 7. Comparison of GRG23 and GRG51, and mutagenesis of differing residues.

Two libraries were generated to assess the permutations of amino acid sequences possible from comparison of the amino acid sequences of GRG23 and GRG51. The first library introduced variation from the GRG51 amino acid sequence into a *grg23(ace2)* coding region. The second library introduced the variation from GRG23(ACE2) amino acid sequence into the *grg51* coding region.

Clones of the resulting libraries were assessed for (1) ability to confer glyphosate resistance upon on a cell, and (2) activity after prolonged incubation at 37°C. A total of ten clones was sequenced and analyzed in more detail. One particular clone, herein designated *grg51.4* (SEQ ID NO:12), encoding the protein GRG51.4 (SEQ ID NO:13), contains several amino acid changes relative to both GRG23(ACE2) and GRG51. The amino acid changes present in GRG51.4 relative to GRG23(ACE2) were subsequently introduced into the *grg23(ace2)* gene, to yield *grg23(ace3)* (SEQ ID NO:14), which encodes the GRG23(ACE3) protein (SEQ ID NO:15). GRG23(ACE3) exhibits superior activity and thermostability relative to GRG23, and GRG23(ACE2).

GRG23(ace1) was mutagenized, and clones were tested to identify clones expressing variants with improved thermostability and/or activity. One clone, *grg23(L5P2.J2)* (SEQ ID NO:16), encoding GRG23(L5P2.J2) (SEQ ID NO:17), was identified by virtue of its improved kinetic properties. GRG23(L5P2.J2) contains three amino acid changes relative to GRG23 (ACE1), as shown in the following Table 4.

Table 4. Amino Acid changes in GRG23(L5P2.J2)

Amino Acid (AA) in GRG23(L5P2.J2) relative to GRG23(ACE1)
V101→F
A213→S
D284→N

Oligonucleotide mutagenesis was used to modify the *grg23(ace3)* coding
 5 region to contain each of the amino acid changes identified in GRG23(L5P2.J2). A
 clone with a gene containing these modifications was identified, and found to encode
 a protein having altered kinetic properties over GRG23(ACE3). This gene was
 designated *grg23(ace4)* (SEQ ID NO:18). The protein encoded by *grg23(ace4)* and
 designated as GRG23(ACE4) (SEQ ID NO:19) contains a single amino acid change
 10 relative to GRG23(ACE3) (Valine 101 to phenylalanine). Based on this result, a
 separate oligonucleotide mutagenesis was performed to test the kinetics of each
 possible amino acid substitution at position 101. None of the amino acid changes
 resulted in further improvement in kinetic properties compared to GRG23(ACE4).
 See Table 5.

15

Table 5. Kinetics of improved variants

	K _m (μM)	K _i (μM)	V _{max} (nmol/min/μg)
GRG23	14	10,800	13
GRG51	15	21,048	13
GRG23(ACE1)	10	14,620	14
GRG23(ACE2)	11	18,104	15
GRG51.4	19	26,610	17
GRG23(ACE3)	15	20,000	17
GRG23(L5P2.J2)	15	2,500	23
GRG23(ACE4)	14	5,010	24

Example 8. Improved thermostability of GRG23 variants

The thermostability of GRG23 and several variants were determined by
 20 incubation of protein samples at 37° C for a range of times, then determining the

residual EPSPS activity as described herein, and comparing the activity to that of a control sample incubated at 4 °C. Table 6 shows that the GRG23 variants GRG23(ACE1), GRG23(ACE2), and GRG23(ACE3) have improved thermostability.

5 Table 6. Thermostability of GRG23 and GRG23 variants

Protein	t _{1/2} at 37°C
GRG23	10.1
GRG23(ACE1)	15.3
GRG23(ACE2)	34.2
GRG23(ACE3)	65.4

Example 9. Variants of *grg23(ace3)*

Oligonucleotide mutagenesis was utilized to generate variants of *grg23(ace3)* that result in expression of proteins with modifications to amino acid residues corresponding to positions 169 to 174 of SEQ ID NO:15. Mutagenesis reactions were carried out using the QuickChange® kit (Stratagene) according to the manufacturer's instructions. Plasmid clones were transformed into *E. coli* cell line BL21*DE3, and expression of proteins induced by IPTG as known in the art. The proteins were purified by affinity binding to a nickel column (TALON metal affinity resin, Clontech). The native GRG23(ace3) protein was also expressed and purified for use as a control. Following purification of each enzyme, protein concentration was measured by Bradford assay as known in the art.

Example 10. Kinetic Analysis of GRG23(ace3) variants

GRG23(ace3) variants GRG23(ace3) R173K (SEQ ID NO:29, encoded by SEQ ID NO:28), GRG23(ace3) G169V/L170V (SEQ ID NO:31, encoded by SEQ ID NO:30), GRG23(ace3) R173Q (SEQ ID NO:33, encoded by SEQ ID NO:32), and GRG23(ace3) I174V (SEQ ID NO:35, encoded by SEQ ID NO:34) were characterized by enzymatic assays as described herein, and compared to the native GRG23(ace3) enzyme. For each enzyme the Km(app) was determined at each of several glyphosate concentrations, and a plot of Km(app) vs. glyphosate concentration was used to calculate the Ki for each enzyme. The thermostability for each enzyme was assessed by incubating the enzyme at 37°C for 16 hours, and then quantifying the

enzymatic activity remaining (as V_{max}) vs. control enzyme that was incubated at 4°C.

Kinetic analysis reveals that GRG23(ace3)R173K, GRG23(ace3)R173Q, GRG23(ace3)I174V and GRG23(ace3)G169V/L170V are virtually indistinguishable from native GRG23(ace3) and show nearly identical catalytic rate, extremely high resistance to glyphosate, and very good affinity for PEP. The observed K_m for PEP of 19 μ M for G169V/L170V (vs 15 μ M for GRG23(ace3)) may represent a slightly lower binding affinity for PEP relative to GRG23(ace3). Each of the four variants had a thermostability of greater than 95% after 16 hours at 37°C. The kinetic values determined for the GRG23(ace3) variants GRG23(ace3) R173K, GRG23(ace3) R173Q, and GRG23(ace3) I174V are shown in Table 6.

Table 7. Kinetics of GRG23(ace3) variants

	K_m (μ M)	K_i (mM)	V_{max} (nmol/min/ μ g)
GRG23(ace3)	16	14	16
GRG23(ace3) R173K	16.6	14.7	17.7
GRG23(ace3) R173Q	14.3	14.2	15.8
GRG23(ace3) I174V	15.5	15.0	15.5

Example 11. Cloning of *syngrg23* and *grg23* variants into a plant expression cassette.

For *syngrg23*, and each of the *grg23* variants described herein (including, for example, *grg23(ace1)*, *grg23(ace2)*, *grg23(ace3)*, *grg23(ace4)*, *grg23(ace3)R173K*, *grg23(ace3)R173Q*, *grg23(ace3)I174V*, *grg23(ace3)G169V/L170V* and *grg23(L5P2.J2)*), the open reading frame (ORF) is amplified by PCR from a full-length DNA template. *Hind* III restriction sites are added to each end of the ORFs during PCR. Additionally, the nucleotide sequence ACC is added immediately 5' to the start codon of the gene to increase translational efficiency (Kozak (1987) *Nucleic Acids Research* 15:8125-8148; Joshi (1987) *Nucleic Acids Research* 15:6643-6653). The PCR product is cloned and sequenced using techniques well known in the art to ensure that no mutations are introduced during PCR.

The plasmid containing the PCR product is digested with *Hind* III and the fragment containing the intact ORF is isolated. This fragment is cloned into the *Hind*

III site of a plasmid such as pAX200, a plant expression vector containing the rice actin promoter (McElroy *et al.* (1991) *Molec. Gen. Genet.* 231:150-160) and the PinII terminator (An *et al.* (1989) *The Plant Cell* 1:115-122). The promoter – gene – terminator fragment from this intermediate plasmid is then subcloned into plasmid pSB11 (Japan Tobacco, Inc.) to form a final pSB11-based plasmid. In some cases, it may be preferable to generate an alternate construct in which a chloroplast leader sequence is encoded as a fusion to the N-terminus of the *syngrg23*, *grg23(ace1)*, *grg23(ace2)*, *grg23(ace3)*, *grg23(ace4)*, *grg23(L5P2.J2)*, *grg23(ace3)R173K*, *grg23(ace3)R173Q*, *grg23(ace3)I174V*, or *grg23(ace3)G169V/L170V* constructs.

These pSB11-based plasmids are typically organized such that the DNA fragment containing the promoter – *gene*– terminator construct, or promoter-chloroplast leader-*gene*-terminator construct may be excised by double digestion by restriction enzymes, such as *Kpn* I and *Pme* I, and used for transformation into plants by aerosol beam injection. The structure of the resulting pSB11-based clones is verified by restriction digest and gel electrophoresis, and by sequencing across the various cloning junctions.

The plasmid is mobilized into *Agrobacterium tumefaciens* strain LBA4404 which also harbors the plasmid pSB1 (Japan Tobacco, Inc.), using triparental mating procedures well known in the art, and plating on media containing spectinomycin.

The pSB11-based plasmid clone carries spectinomycin resistance but is a narrow host range plasmid and cannot replicate in *Agrobacterium*. Spectinomycin resistant colonies arise when pSB11-based plasmids integrate into the broad host range plasmid pSB1 through homologous recombination. The cointegrate product of pSB1 and the pSB11-based plasmid is verified by Southern hybridization. The *Agrobacterium* strain harboring the cointegrate is used to transform maize by methods known in the art, such as, for example, the PureIntro method (Japan Tobacco).

Example 12. Transformation of Plant Cells by *Agrobacterium*-Mediated Transformation

Maize ears are best collected 8-12 days after pollination. Embryos are isolated from the ears, and those embryos 0.8-1.5 mm in size are preferred for use in transformation. Embryos are plated scutellum side-up on a suitable incubation media, such as DN62A5S media (3.98 g/L N6 Salts; 1 ml/L (of 1000x Stock) N6 Vitamins; 800 mg/L L-Asparagine; 100 mg/L Myo-inositol; 1.4 g/L L-Proline; 100 mg/L

Casamino acids; 50 g/L sucrose; 1 ml/L (of 1 mg/ml stock) 2,4-D). However, media and salts other than DN62A5S are suitable and are known in the art. Embryos are incubated overnight at 25°C in the dark. However, it is not necessary *per se* to incubate the embryos overnight.

5 The resulting explants are transferred to mesh squares (30-40 per plate), transferred onto osmotic media for about 30-45 minutes, then transferred to a beaming plate (see, for example, PCT Publication No. WO/0138514 and U.S. Patent No. 5,240,842).

10 DNA constructs designed to express the GRG proteins of the present invention in plant cells are accelerated into plant tissue using an aerosol beam accelerator, using conditions essentially as described in PCT Publication No. WO/0138514. After beaming, embryos are incubated for about 30 min on osmotic media, and placed onto incubation media overnight at 25°C in the dark. To avoid unduly damaging beamed explants, they are incubated for at least 24 hours prior to transfer to recovery media.

15 Embryos are then spread onto recovery period media, for about 5 days, 25°C in the dark, then transferred to a selection media. Explants are incubated in selection media for up to eight weeks, depending on the nature and characteristics of the particular selection utilized. After the selection period, the resulting callus is transferred to embryo maturation media, until the formation of mature somatic embryos is observed.

20 The resulting mature somatic embryos are then placed under low light, and the process of regeneration is initiated by methods known in the art. The resulting shoots are allowed to root on rooting media, and the resulting plants are transferred to nursery pots and propagated as transgenic plants.

25

30

Materials**DN62A5S Media**

Components	per liter	Source
Chu's N6 Basal Salt Mixture (Prod. No. C 416)	3.98 g/L	Phytotechnology Labs
Chu's N6 Vitamin Solution (Prod. No. C 149)	1 ml/L (of 1000x Stock)	Phytotechnology Labs
L-Asparagine	800 mg/L	Phytotechnology Labs
Myo-inositol	100 mg/L	Sigma
L-Proline	1.4 g/L	Phytotechnology Labs
Casamino acids	100 mg/L	Fisher Scientific
Sucrose	50 g/L	Phytotechnology Labs
2, 4-D (Prod. No. D-7299)	1 ml/L (of 1 mg/ml Stock)	Sigma

Adjust the pH of the solution to pH 5.8 with 1N KOH/1N KCl, add Gelrite
 5 (Sigma) to 3g/L, and autoclave. After cooling to 50°C, add 2 ml/L of a 5 mg/ml stock solution of Silver Nitrate (Phytotechnology Labs). Recipe yields about 20 plates.

Example 13. Transformation of EPSP synthase enzymes into Maize Plant Cells by *Agrobacterium*-Mediated Transformation

10 Ears are best collected 8-12 days after pollination. Embryos are isolated from the ears, and those embryos 0.8-1.5 mm in size are preferred for use in transformation. Embryos are plated scutellum side-up on a suitable incubation media, and incubated overnight at 25°C in the dark.

However, it is not necessary *per se* to incubate the embryos overnight.
 15 Embryos are contacted with an *Agrobacterium* strain containing the appropriate vectors having an EPSP synthase enzyme of the present invention for Ti plasmid mediated transfer for about 5-10 min, and then plated onto co-cultivation media for about 3 days (25°C in the dark). After co-cultivation, explants are transferred to recovery period media for about five days (at 25°C in the dark). Explants are
 20 incubated in selection media for up to eight weeks, depending on the nature and characteristics of the particular selection utilized. After the selection period, the resulting callus is transferred to embryo maturation media, until the formation of

53645-19

mature somatic embryos is observed. The resulting mature somatic embryos are then placed under low light, and the process of regeneration is initiated as known in the art. The resulting shoots are allowed to root on rooting media, and the resulting plants are transferred to nursery pots and propagated as transgenic plants.

5 All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

SEQUENCE LISTING IN ELECTRONIC FORM

In accordance with Section 111(1) of the Patent Rules, this description contains a sequence listing in electronic form in ASCII text format (file: 62451-1052 Seq 20-MAY-09 v1.txt).

A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office.

The sequences in the sequence listing in electronic form are reproduced in the following table.

SEQUENCE TABLE

<110> Laura C. Schouten
Cheryl L. Peters
Brian Vande Berg
Todd K. Hinson

<120> IMPROVED GRG23 EPSP SYNTHASES:
COMPOSITIONS AND METHODS OF USE

<130> 45600/336802

<150> 60/972,502

<151> 2007-09-14

<150> 60/872,200

<151> 2006-12-01

<150> 60/861,455

<151> 2006-11-29

<160> 35

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1892

<212> DNA

<213> *Arthrobacter globiformis*

<220>

<221> CDS

<222> (178)...(1417)

<220>

<221> misc_feature

<222> 1801

<223> n = A,T,C or G

<400> 1

```

gggaccacat gctgctcctg atttcagggc tgctgccggt atggaccagg gtttagagag 60
ggacggcacg catcggggcc cttatcggac caacgccaac agcggtcggt ggccttggag 120

cggggccagc acggccgata acgtagactc tttggagctt cgctcgaaag gatcacc atg 180
                                                    Met
                                                    1

gaa act gat cga cta gtg atc cca gga tcg aaa agc atc acc aac cgg 228
Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn Arg
           5                10                15

gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg aga 276
Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val Arg
           20                25                30

cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca att cag gcc 324
Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln Ala
           35                40                45

ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa ggc 372
Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu Gly
           50                55                60                65

ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gat gca 420
Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp Ala
           70                75                80

ggt acc gtg gcc cgg ttc ctc cct cca ttc gtc gcc gca gga cag ggg 468
Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln Gly
           85                90                95

aag ttc acc gtc gac gga agc gag cag ctg cgg cgg cgc ccg ctt cgg 516
Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu Arg
           100                105                110

ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc gag 564
Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser Glu
           115                120                125

cag ctg ccc cta aca att gaa gcg agc ggg ctg gca ggc ggg gag tac 612
Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu Tyr
           130                135                140                145

```

gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc atg	660
Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile Met	
150 155 160	
gcc gcc ccg tac gcg cga caa ggc ctg cgt gtg cgg ata cca aat ccc	708
Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn Pro	
165 170 175	
gtg agc cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac ttc	756
Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp Phe	
180 185 190	
ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct ccc ggg	804
Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro Gly	
195 200 205	
cgc tac aca gcc cgg cgg tat gaa att gaa ccg gac gcg tca act gcg	852
Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr Ala	
210 215 220 225	
tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc cga agc ttc gaa ttc	900
Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu Phe	
230 235 240	
cag ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc aat	948
Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe Asn	
245 250 255	
gta ctt ggg cgg ctc ggt gca gag gtc cac tgg gca ccc aac tcg gtc	996
Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser Val	
260 265 270	
acc ata tcc gga ccg gaa agg ctg aac ggc gac att gaa gtg gat atg	1044
Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp Met	
275 280 285	
ggc gag ata tcg gac acc ttc atg aca ctc gcg gcg att gcc cct cta	1092
Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro Leu	
290 295 300 305	
gcc gat gga ccc atc acg ata acc aac att ggc cat gca cgg ttg aag	1140
Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu Lys	
310 315 320	
gaa tcc gac cgc atc tcg gcg atg gaa acc aac ctg cga acg ctc ggt	1188
Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu Gly	
325 330 335	
gta caa acc gac gtc gga cac gac tgg atg cga atc tac ccc tct acc	1236
Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser Thr	
340 345 350	
ccg cac ggc ggc aga gtc aat tgc cac cgg gac cac agg atc gcc atg	1284
Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala Met	
355 360 365	
gcg ttt tca atc ctg gga ctg cga gtg gac ggg att acc ctc gac gac	1332
Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp Asp	
370 375 380 385	
cct caa tgt gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt gga	1380
Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu Gly	
390 395 400	

cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc t agtgacttcc 1427
 Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
 405 410

tctccggcgg acgctaggca tcggaaaacg aatcctgaca tgaccgacct cctcgcgtca 1487
 cggcgtgtct gccggtaccc aagcattctg ccttagccgc ttccgcggcc ccttatgctt 1547
 tctgggtgtc cagattttca tccgggatgt tgcctgacct tgagcagggc aatcagctgt 1607
 tcagcactgt caatggtgtg ggccctgaag gcggcttcga tggctgccac gtcggcggct 1667
 ctcacgctg tcacgacacg cagatgcgct tcataggcac gttcaggatc cgccctcgtc 1727
 gcctgatacct gagccaaggc aatagttaga tgtgcctccg ttggcggcca gagccgaagc 1787
 aataaggagt tttncgaggc caccagatt ccccggtgg aaggcgatat gggcttcattg 1847
 ctgaactatg ggggccgat ggaagtgact tttcaactct gccca 1892

<210> 2

<211> 413

<212> PRT

<213> *Arthrobacter globiformis*

<400> 2

Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn
1				5					10					15	
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val
			20					25					30		
Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser	Ala	Phe	Lys	Thr	Ala	Ile	Gln
		35					40					45			
Ala	Leu	Gly	Ala	Asn	Val	Ser	Ala	Asp	Gly	Asp	Asn	Trp	Val	Val	Glu
	50					55					60				
Gly	Leu	Gly	Gln	Ala	Pro	His	Leu	Asp	Ala	Asp	Ile	Trp	Cys	Glu	Asp
65					70					75					80
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln
				85					90					95	
Gly	Lys	Phe	Thr	Val	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu
			100					105					110		
Arg	Pro	Leu	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser
		115				120						125			
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu
	130					135					140				
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile
145					150					155					160
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Arg	Ile	Pro	Asn
				165					170					175	
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp
			180					185					190		
Phe	Gly	Leu	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro
		195					200					205			
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr
	210					215					220				
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Ser	Phe	Glu
225					230					235					240
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe
				245					250					255	
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Pro	Asn	Ser
			260					265					270		
Val	Thr	Ile	Ser	Gly	Pro	Glu	Arg	Leu	Asn	Gly	Asp	Ile	Glu	Val	Asp
		275					280					285			
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro
	290					295					300				
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu
305					310					315					320
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Thr	Asn	Leu	Arg	Thr	Leu
				325					330					335	
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser
			340					345					350		

Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala
		355					360					365			
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp
	370					375					380				
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu
385					390					395					400
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly			
				405					410						

<210> 3

<211> 436

<212> PRT

<213> *Arthrobacter globiformis*

<400> 3

Met	Ala	Leu	Glu	Arg	Gly	Gln	His	Gly	Arg	Ser	Arg	Arg	Leu	Phe	Gly
1				5				10					15		
Ala	Ser	Leu	Glu	Arg	Ile	Thr	Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro
		20						25				30			
Gly	Ser	Lys	Ser	Ile	Thr	Asn	Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala
		35				40						45			
Lys	Gly	Thr	Ser	Val	Leu	Val	Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser
	50					55					60				
Ala	Phe	Lys	Thr	Ala	Ile	Gln	Ala	Leu	Gly	Ala	Asn	Val	Ser	Ala	Asp
65					70					75					80
Gly	Asp	Asn	Trp	Val	Val	Glu	Gly	Leu	Gly	Gln	Ala	Pro	His	Leu	Asp
			85					90						95	
Ala	Asp	Ile	Trp	Cys	Glu	Asp	Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro
			100					105					110		
Pro	Phe	Val	Ala	Ala	Gly	Gln	Gly	Lys	Phe	Thr	Val	Asp	Gly	Ser	Glu
		115					120					125			
Gln	Leu	Arg	Arg	Arg	Pro	Leu	Arg	Pro	Leu	Val	Asp	Gly	Ile	Arg	His
	130					135					140				
Leu	Gly	Ala	Arg	Val	Ser	Ser	Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala
145					150					155					160
Ser	Gly	Leu	Ala	Gly	Gly	Glu	Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser
				165					170					175	
Gln	Phe	Ala	Ser	Gly	Leu	Ile	Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly
		180						185					190		
Leu	Arg	Val	Arg	Ile	Pro	Asn	Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met
		195				200						205			
Thr	Leu	Arg	Met	Met	Arg	Asp	Phe	Gly	Leu	Glu	Thr	Ser	Thr	Asp	Gly
	210					215					220				
Ala	Thr	Val	Ser	Val	Pro	Pro	Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu
225					230					235					240
Ile	Glu	Pro	Asp	Ala	Ser	Thr	Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala
				245					250					255	
Val	Ser	Gly	Arg	Ser	Phe	Glu	Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile
			260					265					270		
Gln	Gly	Asp	Thr	Ser	Phe	Phe	Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu
		275					280					285			
Val	His	Trp	Ala	Pro	Asn	Ser	Val	Thr	Ile	Ser	Gly	Pro	Glu	Arg	Leu
	290					295					300				
Asn	Gly	Asp	Ile	Glu	Val	Asp	Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met
305					310					315					320
Thr	Leu	Ala	Ala	Ile	Ala	Pro	Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr
				325					330					335	
Asn	Ile	Gly	His	Ala	Arg	Leu	Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met
			340					345					350		
Glu	Thr	Asn	Leu	Arg	Thr	Leu	Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp
		355					360					365			
Trp	Met	Arg	Ile	Tyr	Pro	Ser	Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys
	370					375						380			

His Arg Asp His Arg Ile Ala Met Ala Phe Ser Ile Leu Gly Leu Arg
 385 390 395 400
 Val Asp Gly Ile Thr Leu Asp Asp Pro Gln Cys Val Gly Lys Thr Phe
 405 410 415
 Pro Gly Phe Phe Asp Tyr Leu Gly Arg Leu Phe Pro Glu Lys Ala Leu
 420 425 430
 Thr Leu Pro Gly
 435

<210> 4
 <211> 1242
 <212> DNA
 <213> iUnknown

<220>
 <223> isolated from soil sample

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 4
 atg gaa act gat cga cta gtg atc cca gga tcg aaa agc atc acc aac 48
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 cgg gct ttg ctt ttg gct gcc gca gcg aag ggc gcg tcg gtc ctg gtg 96
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Ala Ser Val Leu Val
 20 25 30
 aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca att cag 144
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 gcc ctc ggt gcc aac gtc tca gcg gac ggt gat gat tgg gtc gtt gaa 192
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 ggc ctg ggc cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gat 240
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 gcc ggt acc gtg gcc cgg ttc ctc cct cca ttc gtc gcc gca gga cag 288
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 ggg aag ttc acc gtc gac gga agc gag cag ctg cgg cgg cgc ccg ctt 336
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc 384
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 gag cag ctg ccc cta acg att gaa gcg agc ggg ctg gca ggc ggg gag 432
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggt ctg atc 480
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160

atg gcc gcc ccg tac gcg cga caa ggc ctg cgt gtt cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg agc cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc att gag acc agc acc gac gga gcg acc gtc agc gtt cct ccc	624
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcg cgg cgg tat gag att gaa ccg gac gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc cgg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	
ttc cag ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggc gca gag gtc cac tgg gca tcc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser	
260 265 270	
gtc acc ata tcc gga ccg gaa agg ctg acc ggc gac att gaa gtg gat	864
Val Thr Ile Ser Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag ata tcg gac acc ttc atg aca ctg gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
cta gcc gat gga ccc atc acg ata aca aac att ggc cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tcg gcg atg gaa agc aac ctt cga atg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Met Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg cga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggc aga gtc aat tgc cac cgg gac cac agg atc gcc	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg cga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgt gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccg gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	

<210> 5
 <211> 413
 <212> PRT
 <213> iUnknown

<220>
 <223> isolated from soil sample

<400> 5
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Ala Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
 165 170 175
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205
 Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
 210 215 220
 Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu
 225 230 235 240
 Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
 245 250 255
 Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser
 260 265 270
 Val Thr Ile Ser Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp
 275 280 285
 Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
 290 295 300
 Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
 305 310 315 320
 Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Met Leu
 325 330 335
 Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
 340 345 350
 Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
 355 360 365
 Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370 375 380
 Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
 405 410

<210> 6
 <211> 1242
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> synthetic grg23

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 6
 atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac 48
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg 96
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag 144
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 gcc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa 192
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
 50 55 60
 ggc ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac 240
 Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag 288
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt 336
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 cgg ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc 384
 Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag 432
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc 480
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat 528
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
 165 170 175
 ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac 576
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct cca 624
 Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205

ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc acc ata tct gga ccg gaa agg ctg aac ggc gac att gaa gtg gat	864
Val Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	

<210> 7

<211> 413

<212> PRT

<213> Artificial Sequence

<220>

<223> synthetic GRG23

<400> 7

Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn
1				5					10					15	

```

Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
      20                      25                      30
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
      35                      40                      45
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
      50                      55                      60
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp
      65                      70                      75                      80
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
      85                      90                      95
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
      100                     105                     110
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
      115                     120                     125
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
      130                     135                     140
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
      145                     150                     155                     160
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
      165                     170                     175
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
      180                     185                     190
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
      195                     200                     205
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
      210                     215                     220
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu
      225                     230                     235                     240
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
      245                     250                     255
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser
      260                     265                     270
Val Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp
      275                     280                     285
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
      290                     295                     300
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
      305                     310                     315                     320
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu
      325                     330                     335
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
      340                     345                     350
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
      355                     360                     365
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
      370                     375                     380
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
      385                     390                     395                     400
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
      405                     410

```

<210> 8
 <211> 1242
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23(ace1)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 8

atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac	48
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg	96
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag	144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
acc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa	192
Thr Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
ggc ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	

aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc acc ata act gga ccg gaa agg ctg aac ggc gac att gaa gtg gat	864
Val Thr Ile Thr Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	

<210> 9
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (ACE1)

<400> 9	
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
Arg Ala Leu Leu Leu Ala Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
Thr Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	

Arg	Pro	Leu	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser		
		115					120					125					
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu		
	130					135					140						
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile		
145					150					155					160		
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Arg	Ile	Pro	Asn		
				165					170					175			
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp		
			180					185					190				
Phe	Gly	Leu	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro		
	195						200					205					
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr		
	210					215					220						
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Ser	Phe	Glu		
225					230					235					240		
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe		
			245						250					255			
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Pro	Asn	Ser		
		260						265					270				
Val	Thr	Ile	Thr	Gly	Pro	Glu	Arg	Leu	Asn	Gly	Asp	Ile	Glu	Val	Asp		
	275						280					285					
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro		
	290				295						300						
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu		
305					310					315					320		
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Thr	Asn	Leu	Arg	Thr	Leu		
			325						330					335			
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser		
		340						345					350				
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala		
		355					360					365					
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp		
	370					375					380						
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu		
385					390					395					400		
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly					
			405						410								

<210> 10
 <211> 1242
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23(ace2)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 10																	
atg	gaa	act	gat	cgc	ctt	gtg	atc	cca	gga	tcg	aaa	agc	atc	acc	aac		48
Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn		
1				5					10					15			
cgg	gct	ttg	ctt	ttg	gct	gcc	gca	gcg	aag	ggc	acg	tcg	gtc	ctg	gtg		96
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val		
			20					25					30				
aga	cca	ttg	gtc	agc	gcc	gat	acc	tca	gca	ttc	aaa	act	gca	atc	cag		144
Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser	Ala	Phe	Lys	Thr	Ala	Ile	Gln		
		35					40					45					

gcc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa	192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
ggc ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc acc ata cgg gga ccg gaa agg ctg aac ggc gac att gaa gtg gat	864
Val Thr Ile Arg Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	

ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggg gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	

<210> 11
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (ACE2)

<400> 11

Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
Arg Ala Leu Leu Leu Ala Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	

Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr	
210						215					220					
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Ser	Phe	Glu	
225					230					235					240	
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe	
				245					250					255		
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Pro	Asn	Ser	
			260					265					270			
Val	Thr	Ile	Arg	Gly	Pro	Glu	Arg	Leu	Asn	Gly	Asp	Ile	Glu	Val	Asp	
		275					280					285				
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro	
	290				295						300					
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu	
305					310					315					320	
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Thr	Asn	Leu	Arg	Thr	Leu	
				325					330					335		
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser	
			340					345					350			
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala	
		355					360					365				
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp	
	370					375					380					
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu	
385					390					395					400	
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly				
				405					410							

<210> 12
 <211> 1242
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg51.4

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 12																
atg	gaa	act	gat	cga	cta	gtg	atc	cca	gga	tcg	aaa	agc	atc	acc	aac	48
Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn	
1				5					10					15		
cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg																96
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val	
			20					25					30			
aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca att cag																144
Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser	Ala	Phe	Lys	Thr	Ala	Ile	Gln	
		35					40					45				
gcc ctc ggt gcc aac gtc tca gcg gac ggt gat gat tgg gtc gtt gaa																192
Ala	Leu	Gly	Ala	Asn	Val	Ser	Ala	Asp	Gly	Asp	Asp	Trp	Val	Val	Glu	
	50					55				60						
ggc ctg ggc cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gat																240
Gly	Leu	Gly	Gln	Ala	Pro	Asn	Leu	Asp	Ala	Asp	Ile	Trp	Cys	Glu	Asp	
	65				70				75					80		
gcc ggt acc gtg gcc cgg ttc ctc cct cca ttc gtc gcc gca gga cag																288
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln	
				85					90					95		

ggg aag ttc acc gtc gac gga agc gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc cta acg att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggt ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg cga caa ggc ctg cgt gtt cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg agc cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc att gag acc agc acc gac gga gcg acc gtc agc gtt cct ccc	624
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcg cgg cgg tat gag att gaa ccg gac gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc cgg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	
ttc cag ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggc gca gag gtc cac tgg gca tcc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser	
260 265 270	
gtc acc ata cgc gga ccg gaa agg ctg acc ggc gac att gaa gtg gat	864
Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag ata tcg gac acc ttc atg aca ctg gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
cta gcc gat gga ccc atc acg ata aca aac att ggc cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tcg gcg atg gaa agc aac ctt cga acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg cga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	

```

acc ccg cac ggc ggc aga gtc aat tgc cac cgg gac cac agg atc gcc 1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
      355                360                365

atg gcg ttt tca atc ctg gga ctg cga gtg gac ggg att acc ctc gac 1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
      370                375                380

gac cct caa tgt gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt 1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
385                390                395                400

gga cgc ctt ttc ccg gaa aag gcg ctt acg ctc ccc ggc tag 1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
      405                410

```

```

<210> 13
<211> 413
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> GRG51.4

```

```

<400> 13
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1          5          10          15
Arg Ala Leu Leu Leu Ala Ala Ala Ala Lys Gly Thr Ser Val Leu Val
      20          25          30
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
      35          40          45
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
      50          55          60
Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
      65          70          75          80
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
      85          90          95
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
      100          105          110
Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
      115          120          125
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
      130          135          140
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
      145          150          155          160
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
      165          170          175
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
      180          185          190
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
      195          200          205
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
      210          215          220
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu
      225          230          235          240
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
      245          250          255
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser
      260          265          270
Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp
      275          280          285
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
      290          295          300

```

Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
 305 310 315 320
 Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu
 325 330 335
 Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
 340 345 350
 Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
 355 360 365
 Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370 375 380
 Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
 405 410

<210> 14
 <211> 1242
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23(ace3)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 14
 atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac 48
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15

 cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg 96
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30

 aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag 144
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45

 gcc ctc ggt gcc aac gtc tca gcc gac ggt gac gat tgg gtc gtt gaa 192
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60

 ggc ctg ggt cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gac 240
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80

 gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag 288
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95

 ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt 336
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110

 cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc 384
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125

 gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag 432
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140

tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc att gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc ccg ccg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg ccg ctc ggt gcg gag gtc cac tgg gca tcc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser	
260 265 270	
gtc acc ata cgt gga ccg gaa agg ctg acc ggc gac att gaa gtg gat	864
Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa agc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac ccg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	

gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
 405 410

1242

<210> 15
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (ACE3)

<400> 15
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
 165 170 175
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205
 Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
 210 215 220
 Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu
 225 230 235 240
 Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
 245 250 255
 Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser
 260 265 270
 Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp
 275 280 285
 Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
 290 295 300
 Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
 305 310 315 320
 Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu
 325 330 335
 Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
 340 345 350
 Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
 355 360 365
 Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370 375 380
 Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400

Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
 405 410

<210> 16
 <211> 1242
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23 (L5P2.J2)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 16
 atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac 48
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg 96
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag 144
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 acc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa 192
 Thr Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
 50 55 60
 ggc ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac 240
 Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag 288
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 ggg aag ttc acc ttc gac gga tca gag cag ctg cgg cgg cgc ccg ctt 336
 Gly Lys Phe Thr Phe Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 cgg ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc 384
 Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 gag cag ctg ccc ctt aca att gaa gcg agt ggg ctg gca ggc ggg gag 432
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc 480
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat 528
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
 165 170 175
 ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac 576
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190

ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca tcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ser Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc acc ata act gga ccg gaa agg ctg aac ggc aac att gaa gtg gat	864
Val Thr Ile Thr Gly Pro Glu Arg Leu Asn Gly Asn Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	

<210> 17
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (L5P2.J2)

<400> 17

Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn
1				5					10					15	
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val
			20					25					30		
Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser	Ala	Phe	Lys	Thr	Ala	Ile	Gln
		35					40					45			
Thr	Leu	Gly	Ala	Asn	Val	Ser	Ala	Asp	Gly	Asp	Asn	Trp	Val	Val	Glu
	50					55					60				
Gly	Leu	Gly	Gln	Ala	Pro	His	Leu	Asp	Ala	Asp	Ile	Trp	Cys	Glu	Asp
65					70					75					80
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln
				85					90					95	
Gly	Lys	Phe	Thr	Phe	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu
			100					105					110		
Arg	Pro	Leu	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser
		115					120					125			
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu
	130					135					140				
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile
145					150					155					160
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Arg	Ile	Pro	Asn
				165					170					175	
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp
			180					185					190		
Phe	Gly	Leu	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro
		195					200					205			
Gly	Arg	Tyr	Thr	Ser	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr
	210					215					220				
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Ser	Phe	Glu
225					230					235					240
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe
				245					250					255	
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Pro	Asn	Ser
			260					265					270		
Val	Thr	Ile	Thr	Gly	Pro	Glu	Arg	Leu	Asn	Gly	Asn	Ile	Glu	Val	Asp
		275					280					285			
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro
	290					295					300				
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu
305					310					315					320
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Thr	Asn	Leu	Arg	Thr	Leu
				325					330					335	
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser
			340					345					350		
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala
		355					360					365			
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp
	370					375					380				
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu
385					390					395					400
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly			
				405					410						

<210> 18

<211> 1242

<212> DNA

<213> Artificial Sequence

<220>

<223> grg23(ace4)

<220>

<221> CDS

<222> (1)...(1242)

<400> 18

atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac	48
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg	96
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag	144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
gcc ctc ggt gcc aac gtc tca gcc gac ggt gac gat tgg gtc gtt gaa	192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu	
50 55 60	
ggc ctg ggt cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
ggg aag ttc acc ttc gac gga tca gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Phe Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc att gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	

ttt	caa	ggc	ctt	ggc	aca	gac	agc	atc	caa	ggc	gac	acg	tca	ttc	ttc	768
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe	
				245					250					255		
aat	gta	ctt	ggg	cgg	ctc	ggt	gcg	gag	gtc	cac	tgg	gca	tcc	aac	tcg	816
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Ser	Asn	Ser	
			260					265					270			
gtc	acc	ata	cgg	gga	ccg	gaa	agg	ctg	acc	ggc	gac	att	gaa	gtg	gat	864
Val	Thr	Ile	Arg	Gly	Pro	Glu	Arg	Leu	Thr	Gly	Asp	Ile	Glu	Val	Asp	
		275					280					285				
atg	ggc	gag	att	tcg	gac	acc	ttc	atg	aca	ctc	gcg	gcg	att	gcc	cct	912
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro	
	290					295					300					
ttg	gcc	gat	gga	ccc	atc	acg	ata	acc	aac	att	ggt	cat	gca	cgg	ttg	960
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu	
305					310				315					320		
aag	gaa	tcc	gac	cgc	atc	tca	gcg	atg	gaa	agc	aac	ctg	cgc	acg	ctc	1008
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Ser	Asn	Leu	Arg	Thr	Leu	
				325					330				335			
ggt	gta	caa	acc	gac	gtc	gga	cac	gac	tgg	atg	aga	atc	tac	ccc	tct	1056
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser	
			340					345					350			
acc	ccg	cac	ggc	ggt	aga	gtg	aat	tgc	cac	cgg	gac	cac	agg	atc	gct	1104
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala	
		355					360					365				
atg	gcg	ttt	tca	atc	ctg	gga	ctg	aga	gtg	gac	ggg	att	acc	ctc	gac	1152
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp	
	370					375					380					
gac	cct	caa	tgc	gtc	ggg	aag	acc	ttt	cct	ggc	ttc	ttc	gac	tac	ctt	1200
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu	
385					390					395				400		
gga	cgc	ctt	ttc	ccc	gaa	aag	gcg	ctt	acg	ctc	ccc	ggc	tag			1242
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly	*			
				405					410							

<210> 19
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (ACE4)

<400> 19
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80

Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln	
				85				90						95		
Gly	Lys	Phe	Thr	Phe	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu	
			100					105					110			
Arg	Pro	Val	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser	
		115					120					125				
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu	
	130					135					140					
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile	
145					150					155					160	
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Arg	Ile	Pro	Asn	
			165					170						175		
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp	
			180					185					190			
Phe	Gly	Ile	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro	
		195					200					205				
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr	
	210					215					220					
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Arg	Phe	Glu	
225					230					235					240	
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe	
			245						250					255		
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Ser	Asn	Ser	
		260						265					270			
Val	Thr	Ile	Arg	Gly	Pro	Glu	Arg	Leu	Thr	Gly	Asp	Ile	Glu	Val	Asp	
		275					280					285				
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro	
	290				295						300					
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu	
305					310					315					320	
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Ser	Asn	Leu	Arg	Thr	Leu	
			325					330						335		
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser	
		340						345					350			
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala	
		355					360					365				
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp	
	370					375					380					
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu	
385					390					395					400	
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly				
			405						410							

<210> 20
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23 (L3P1.B20)

<220>
 <221> CDS
 <222> (1)...(1242)

<400>	20																
atg	gaa	act	gat	cgc	ctt	gtg	atc	cca	gga	tcg	aaa	agc	atc	acc	aac		48
Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn		
1				5					10					15			
cgg	gct	ttg	ctt	ttg	gct	gcc	gca	gcg	aag	ggc	acg	tcg	gtc	ctg	gtg		96
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val		
			20					25					30				

aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag	144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
gcc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa	192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
ggc ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
ggg aag ttc acc gtc gac gga tca gag cag ttg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc ctg gtt gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc atc cct cca	624
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Ile Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc acc ata tct gga ccg gaa agg ctg aac ggc gac att gaa gtg gat	864
Val Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp	
275 280 285	

atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	
gg	1244

<210> 21
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (L3P1.B20)

<400> 21

Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn
1				5					10					15	
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val
			20					25					30		
Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser	Ala	Phe	Lys	Thr	Ala	Ile	Gln
			35				40					45			
Ala	Leu	Gly	Ala	Asn	Val	Ser	Ala	Asp	Gly	Asp	Asn	Trp	Val	Val	Glu
			50			55					60				
Gly	Leu	Gly	Gln	Ala	Pro	His	Leu	Asp	Ala	Asp	Ile	Trp	Cys	Glu	Asp
65					70					75				80	
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln
				85					90					95	
Gly	Lys	Phe	Thr	Val	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu
			100					105					110		
Arg	Pro	Leu	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser
			115				120					125			
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu
			130			135					140				
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile
145					150					155					160

```

Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
      165                      170                      175
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
      180                      185                      190
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Ile Pro Pro
      195                      200                      205
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
      210                      215                      220
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu
225                      230                      235                      240
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
      245                      250                      255
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser
      260                      265                      270
Val Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp
      275                      280                      285
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
      290                      295                      300
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
305                      310                      315                      320
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu
      325                      330                      335
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
      340                      345                      350
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
      355                      360                      365
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
      370                      375                      380
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
385                      390                      395                      400
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
      405                      410

```

<210> 22
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23 (L3P1.B3)

<220>
 <221> CDS
 <222> (1)...(1242)

```

<400> 22
atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac 48
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
  1                      5                      10                      15

cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg 96
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
      20                      25                      30

aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag 144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
      35                      40                      45

gcc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa 192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
      50                      55                      60

```

ggc	ctg	ggt	cag	gca	ccc	cac	ctc	gac	gcc	cac	atc	tgg	tgc	gag	gac	240
Gly	Leu	Gly	Gln	Ala	Pro	His	Leu	Asp	Ala	His	Ile	Trp	Cys	Glu	Asp	
65					70					75					80	
gca	ggt	act	gtg	gcc	cgg	ttc	ctc	cct	cca	ttc	gta	gcc	gca	ggt	cag	288
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln	
				85					90					95		
ggg	aag	ttc	acc	gtc	gac	gga	tca	gag	cag	ctg	cgg	cgg	cgc	ccg	ctt	336
Gly	Lys	Phe	Thr	Val	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu	
			100					105					110			
cgg	ccc	ctg	gtc	gac	ggc	atc	cgc	cac	ctg	ggc	gcc	cgc	gtc	tcc	tcc	384
Arg	Pro	Leu	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser	
		115					120					125				
gag	cag	ctg	ccc	ctt	aca	att	gaa	gcg	agc	ggg	ctg	gca	ggc	ggg	gag	432
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu	
	130					135					140					
tac	gaa	att	gaa	gcc	cat	cag	agc	agc	cag	ttc	gcc	tcc	ggc	ctg	atc	480
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile	
145					150					155					160	
atg	gcc	gcc	ccg	tac	gcg	aga	caa	ggc	ctg	cgt	gtg	cgg	ata	cca	aat	528
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Arg	Ile	Pro	Asn	
				165					170					175		
ccc	gtg	tca	cag	ccc	tac	ctc	acg	atg	aca	ctg	cgg	atg	atg	agg	gac	576
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp	
			180					185					190			
ttc	ggc	ctt	gag	acc	agc	acc	gac	gga	gcc	acc	gtc	agc	gtc	cct	cca	624
Phe	Gly	Leu	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro	
		195					200					205				
ggg	cgc	tac	aca	gcc	cgg	cgg	tat	aaa	ata	gaa	ccg	gat	gcg	tca	act	672
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Lys	Ile	Glu	Pro	Asp	Ala	Ser	Thr	
	210					215					220					
gcg	tcg	tac	ttc	gcc	gcc	gct	tcc	gcc	gtc	tct	ggc	agg	agc	ttc	gaa	720
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Ser	Phe	Glu	
225					230					235					240	
ttt	caa	ggc	ctt	ggc	aca	gac	agc	atc	caa	ggc	gac	acg	tca	ttc	ttc	768
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe	
				245					250					255		
aat	gta	ctt	ggg	cgg	ctc	ggt	gcg	gag	gtc	cac	tgg	gca	ccc	aac	tcg	816
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Pro	Asn	Ser	
			260					265					270			
gtc	acc	ata	tct	gga	ccg	gaa	agg	ctg	aac	ggc	gac	att	gaa	gtg	gat	864
Val	Thr	Ile	Ser	Gly	Pro	Glu	Arg	Leu	Asn	Gly	Asp	Ile	Glu	Val	Asp	
		275					280					285				
atg	ggc	gag	att	tcg	gac	acc	ttc	atg	aca	ctc	gcg	gcg	att	gcc	cct	912
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro	
	290					295					300					
ttg	gcc	gat	gga	ccc	atc	acg	ata	acc	aac	att	ggt	cat	gca	cgg	ttg	960
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu	
305					310					315					320	

```

aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc 1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu
      325      330      335

ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct 1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
      340      345      350

acc ccg cac ggc ggt aga gtg aat tgc cac cga gac cac agg atc gct 1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
      355      360      365

atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac 1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
      370      375      380

gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt 1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
385      390      395      400

gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag 1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
      405      410

gg 1244

```

```

<210> 23
<211> 413
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> GRG23 (L3P1.B3)

```

```

<400> 23
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1      5      10      15
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
      20      25      30
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
      35      40      45
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
      50      55      60
Gly Leu Gly Gln Ala Pro His Leu Asp Ala His Ile Trp Cys Glu Asp
65      70      75      80
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
      85      90      95
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
      100      105      110
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
      115      120      125
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
      130      135      140
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
145      150      155      160
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
      165      170      175
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
      180      185      190
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
      195      200      205
Gly Arg Tyr Thr Ala Arg Arg Tyr Lys Ile Glu Pro Asp Ala Ser Thr
      210      215      220

```

Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Ser	Phe	Glu
225					230					235					240
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe
				245					250					255	
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Pro	Asn	Ser
			260					265					270		
Val	Thr	Ile	Ser	Gly	Pro	Glu	Arg	Leu	Asn	Gly	Asp	Ile	Glu	Val	Asp
		275					280					285			
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro
	290					295					300				
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu
305					310					315					320
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Thr	Asn	Leu	Arg	Thr	Leu
				325					330					335	
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser
			340					345					350		
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala
		355					360					365			
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp
	370					375				380					
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu
385					390					395					400
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly			
				405					410						

<210> 24
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23 (L3P1.F18)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 24	
atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac	48
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg	96
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag	144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
gcc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa	192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
ggc ctg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	

ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc atc ata tct gga ccg gaa agg ctg aac ggc gac att gaa gtg gat	864
Val Ile Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	

acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct 1104
 Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
 355 360 365

atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac 1152
 Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370 375 380

gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt 1200
 Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400

gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag 1242
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
 405 410

gg 1244

<210> 25
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (L3P1.F18)

<400> 25
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
 165 170 175
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205
 Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
 210 215 220
 Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu
 225 230 235 240
 Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
 245 250 255
 Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser
 260 265 270
 Val Ile Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp
 275 280 285

```

Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
 290                               295                   300
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
305                               310                   315                   320
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu
                               325                   330                   335
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
                               340                   345                   350
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
                               355                   360                   365
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370                               375                   380
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
385                               390                   395                   400
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
                               405                   410

```

<210> 26
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23 (L3P1.O23)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 26

atg gaa act gat cac ctt gtg atc cca gga tcg aaa agc atc acc aac	48
Met Glu Thr Asp His Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
cgg gcg ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg	96
Arg Ala Leu Leu Leu Ala Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag	144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
gcc ctc ggt gcc aac gtc tca gcc gac ggt gac aat tgg gtc gtt gaa	192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu	
50 55 60	
ggc ttg ggt cag gca ccc cac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc ctg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	

gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc ctt gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg agc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttt ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca ccc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser	
260 265 270	
gtc acc ata tct gga ccg gaa agg ctg aac ggc gac att gaa gtg gat	864
Val Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa acc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	

gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt 1200
 Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400

gga cgc ctt ttc ccc gaa aag gcg ctt acg ctt ccc ggc tag 1242
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
 405 410

gg 1244

<210> 27
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23 (L3P1.O23)

<400> 27
 Met Glu Thr Asp His Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asn Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro His Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 Arg Pro Leu Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Ile Pro Asn
 165 170 175
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 Phe Gly Leu Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205
 Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
 210 215 220
 Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Ser Phe Glu
 225 230 235 240
 Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
 245 250 255
 Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Pro Asn Ser
 260 265 270
 Val Thr Ile Ser Gly Pro Glu Arg Leu Asn Gly Asp Ile Glu Val Asp
 275 280 285
 Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
 290 295 300
 Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
 305 310 315 320
 Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Thr Asn Leu Arg Thr Leu
 325 330 335
 Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
 340 345 350

```

Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
      355                      360                      365
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
      370                      375                      380
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
385                      390                      395                      400
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
      405                      410

```

<210> 28
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23(ace3) variant sequence (grg23(ace3) R173K)

<220>
 <221> CDS
 <222> (1)...(1242)

```

<400> 28
atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac      48
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
  1                      5                      10                      15

cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg      96
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
      20                      25                      30

aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag      144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
      35                      40                      45

gcc ctc ggt gcc aac gtc tca gcc gac ggt gac gat tgg gtc gtt gaa      192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
      50                      55                      60

ggc ctg ggt cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gac      240
Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
      65                      70                      75                      80

gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag      288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
      85                      90                      95

ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt      336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
      100                      105                      110

cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc      384
Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
      115                      120                      125

gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag      432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
      130                      135                      140

tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc      480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
145                      150                      155                      160

```

atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg aag ata cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Lys Ile Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc att gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca tcc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser	
260 265 270	
gtc acc ata cgg gga ccg gaa agg ctg acc ggc gac att gaa gtg gat	864
Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa agc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	

gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag 1242
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
 405 410

gg 1244

<210> 29
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23(ace3) variant sequence (GRG23(ace3) R173K)

<400> 29
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Lys Ile Pro Asn
 165 170 175
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205
 Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
 210 215 220
 Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu
 225 230 235 240
 Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
 245 250 255
 Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser
 260 265 270
 Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp
 275 280 285
 Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
 290 295 300
 Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
 305 310 315 320
 Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu
 325 330 335
 Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
 340 345 350
 Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
 355 360 365
 Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370 375 380

Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
 405 410

<210> 30
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23(ace3) variant sequence (grg23(ace3)
 G169V/L170V)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 30
 atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac 48
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg 96
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag 144
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 gcc ctc ggt gcc aac gtc tca gcc gac ggt gac gat tgg gtc gtt gaa 192
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 ggc ctg ggt cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gac 240
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag 288
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt 336
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc 384
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag 432
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc 480
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 atg gcc gcc ccg tac gcg aga caa gtc gtg cgt gtg aag ata cca aat 528
 Met Ala Ala Pro Tyr Ala Arg Gln Val Val Arg Val Lys Ile Pro Asn
 165 170 175

ccc	gtg	tca	cag	ccc	tac	ctc	acg	atg	aca	ctg	cgg	atg	atg	agg	gac	576
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp	
			180					185						190		
ttc	ggc	att	gag	acc	agc	acc	gac	gga	gcc	acc	gtc	agc	gtc	cct	cca	624
Phe	Gly	Ile	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro	
		195					200					205				
ggg	cgc	tac	aca	gcc	cgg	cgg	tat	gaa	ata	gaa	ccg	gat	gcg	tca	act	672
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr	
	210					215					220					
gcg	tcg	tac	ttc	gcc	gcc	gct	tcc	gcc	gtc	tct	ggc	agg	cgc	ttc	gaa	720
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Arg	Phe	Glu	
225					230				235						240	
ttt	caa	ggc	ctt	ggc	aca	gac	agc	atc	caa	ggc	gac	acg	tca	ttc	ttc	768
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe	
			245						250					255		
aat	gta	ctt	ggg	cgg	ctc	ggt	gcg	gag	gtc	cac	tgg	gca	tcc	aac	tcg	816
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Ser	Asn	Ser	
			260					265					270			
gtc	acc	ata	cgg	gga	ccg	gaa	agg	ctg	acc	ggc	gac	att	gaa	gtg	gat	864
Val	Thr	Ile	Arg	Gly	Pro	Glu	Arg	Leu	Thr	Gly	Asp	Ile	Glu	Val	Asp	
		275					280					285				
atg	ggc	gag	att	tcg	gac	acc	ttc	atg	aca	ctc	gcg	gcg	att	gcc	cct	912
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro	
	290					295					300					
ttg	gcc	gat	gga	ccc	atc	acg	ata	acc	aac	att	ggt	cat	gca	cgg	ttg	960
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu	
305					310					315					320	
aag	gaa	tcc	gac	cgc	atc	tca	gcg	atg	gaa	agc	aac	ctg	cgc	acg	ctc	1008
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Ser	Asn	Leu	Arg	Thr	Leu	
				325					330					335		
ggt	gta	caa	acc	gac	gtc	gga	cac	gac	tgg	atg	aga	atc	tac	ccc	tct	1056
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser	
			340					345					350			
acc	ccg	cac	ggc	ggt	aga	gtg	aat	tgc	cac	cgg	gac	cac	agg	atc	gct	1104
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala	
		355					360					365				
atg	gcg	ttt	tca	atc	ctg	gga	ctg	aga	gtg	gac	ggg	att	acc	ctc	gac	1152
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp	
	370					375					380					
gac	cct	caa	tgc	gtc	ggg	aag	acc	ttt	cct	ggc	ttc	ttc	gac	tac	ctt	1200
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu	
385					390					395					400	
gga	cgc	ctt	ttc	ccc	gaa	aag	gcg	ctt	acg	ctc	ccc	ggc	tag			1242
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly	*			
				405					410							

gg

1244

<210> 31
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23(ace3) variant sequence (GRG23(ace3)
 G169V/L170V)

<400> 31
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160
 Met Ala Ala Pro Tyr Ala Arg Gln Val Val Arg Val Lys Ile Pro Asn
 165 170 175
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190
 Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205
 Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr
 210 215 220
 Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu
 225 230 235 240
 Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
 245 250 255
 Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser
 260 265 270
 Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp
 275 280 285
 Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
 290 295 300
 Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
 305 310 315 320
 Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu
 325 330 335
 Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
 340 345 350
 Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
 355 360 365
 Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
 370 375 380
 Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
 385 390 395 400
 Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly
 405 410

<210> 32
 <211> 1244
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> grg23(ace3) variant sequence (grg23(ace3) R173Q)

<220>
 <221> CDS
 <222> (1)...(1242)

<400> 32
 atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac 48
 Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
 1 5 10 15

cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg 96
 Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
 20 25 30

aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag 144
 Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
 35 40 45

gcc ctg ggt gcc aac gtc tca gcc gac ggt gac gat tgg gtc gtt gaa 192
 Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
 50 55 60

ggc ctg ggt cag gca ccc aac ctg gac gcc gac atc tgg tgc gag gac 240
 Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp
 65 70 75 80

gca ggt act gtg gcc cgg ttc ctg cct cca ttc gta gcc gca ggt cag 288
 Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln
 85 90 95

ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt 336
 Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu
 100 105 110

cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc 384
 Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser
 115 120 125

gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag 432
 Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu
 130 135 140

tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc 480
 Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile
 145 150 155 160

atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg caa ata cca aat 528
 Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Gln Ile Pro Asn
 165 170 175

ccc gtg tca cag ccc tac ctg acg atg aca ctg cgg atg atg agg gac 576
 Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp
 180 185 190

ttc ggc att gag acc agc acc gac gga gcc acc gtc agc gtc cct cca 624
 Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro
 195 200 205

ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	
ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc	768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe	
245 250 255	
aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca tcc aac tcg	816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser	
260 265 270	
gtc acc ata cgg gga ccg gaa agg ctg acc ggc gac att gaa gtg gat	864
Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp	
275 280 285	
atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct	912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro	
290 295 300	
ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg	960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu	
305 310 315 320	
aag gaa tcc gac cgc atc tca gcg atg gaa agc aac ctg cgc acg ctc	1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu	
325 330 335	
ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct	1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser	
340 345 350	
acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct	1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala	
355 360 365	
atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac	1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp	
370 375 380	
gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt	1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu	
385 390 395 400	
gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag	1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *	
405 410	

gg 1244

<210> 33
 <211> 413
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GRG23(ace3) variant sequence (GRG23(ace3) R173Q)

<400> 33

Met	Glu	Thr	Asp	Arg	Leu	Val	Ile	Pro	Gly	Ser	Lys	Ser	Ile	Thr	Asn
1				5					10					15	
Arg	Ala	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Lys	Gly	Thr	Ser	Val	Leu	Val
		20						25					30		
Arg	Pro	Leu	Val	Ser	Ala	Asp	Thr	Ser	Ala	Phe	Lys	Thr	Ala	Ile	Gln
		35					40					45			
Ala	Leu	Gly	Ala	Asn	Val	Ser	Ala	Asp	Gly	Asp	Asp	Trp	Val	Val	Glu
	50					55					60				
Gly	Leu	Gly	Gln	Ala	Pro	Asn	Leu	Asp	Ala	Asp	Ile	Trp	Cys	Glu	Asp
65					70					75					80
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln
				85					90					95	
Gly	Lys	Phe	Thr	Val	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu
			100					105					110		
Arg	Pro	Val	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser
		115					120					125			
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu
	130					135					140				
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile
145					150					155					160
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Gln	Ile	Pro	Asn
				165					170					175	
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp
			180					185					190		
Phe	Gly	Ile	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro
		195					200					205			
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr
	210					215					220				
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Arg	Phe	Glu
225					230					235					240
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe
				245					250					255	
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Ser	Asn	Ser
		260						265					270		
Val	Thr	Ile	Arg	Gly	Pro	Glu	Arg	Leu	Thr	Gly	Asp	Ile	Glu	Val	Asp
		275					280					285			
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro
	290				295						300				
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu
305					310					315					320
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Ser	Asn	Leu	Arg	Thr	Leu
				325					330					335	
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser
			340					345					350		
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala
		355					360					365			
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp
	370					375					380				
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu
385					390					395					400
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly			
				405					410						

<210> 34

<211> 1244

<212> DNA

<213> Artificial Sequence

<220>

<223> grg23(ace3) variant sequence (grg23(ace3) I174V)

<220>

<221> CDS

<222> (1)...(1242)

<400> 34

atg gaa act gat cgc ctt gtg atc cca gga tcg aaa agc atc acc aac	48
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn	
1 5 10 15	
cgg gct ttg ctt ttg gct gcc gca gcg aag ggc acg tcg gtc ctg gtg	96
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val	
20 25 30	
aga cca ttg gtc agc gcc gat acc tca gca ttc aaa act gca atc cag	144
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln	
35 40 45	
gcc ctc ggt gcc aac gtc tca gcc gac ggt gac gat tgg gtc gtt gaa	192
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu	
50 55 60	
ggc ctg ggt cag gca ccc aac ctc gac gcc gac atc tgg tgc gag gac	240
Gly Leu Gly Gln Ala Pro Asn Leu Asp Ala Asp Ile Trp Cys Glu Asp	
65 70 75 80	
gca ggt act gtg gcc cgg ttc ctc cct cca ttc gta gcc gca ggt cag	288
Ala Gly Thr Val Ala Arg Phe Leu Pro Pro Phe Val Ala Ala Gly Gln	
85 90 95	
ggg aag ttc acc gtc gac gga tca gag cag ctg cgg cgg cgc ccg ctt	336
Gly Lys Phe Thr Val Asp Gly Ser Glu Gln Leu Arg Arg Arg Pro Leu	
100 105 110	
cgg ccc gtg gtc gac ggc atc cgc cac ctg ggc gcc cgc gtc tcc tcc	384
Arg Pro Val Val Asp Gly Ile Arg His Leu Gly Ala Arg Val Ser Ser	
115 120 125	
gag cag ctg ccc ctt aca att gaa gcg agc ggg ctg gca ggc ggg gag	432
Glu Gln Leu Pro Leu Thr Ile Glu Ala Ser Gly Leu Ala Gly Gly Glu	
130 135 140	
tac gaa att gaa gcc cat cag agc agc cag ttc gcc tcc ggc ctg atc	480
Tyr Glu Ile Glu Ala His Gln Ser Ser Gln Phe Ala Ser Gly Leu Ile	
145 150 155 160	
atg gcc gcc ccg tac gcg aga caa ggc ctg cgt gtg cgg gtc cca aat	528
Met Ala Ala Pro Tyr Ala Arg Gln Gly Leu Arg Val Arg Val Pro Asn	
165 170 175	
ccc gtg tca cag ccc tac ctc acg atg aca ctg cgg atg atg agg gac	576
Pro Val Ser Gln Pro Tyr Leu Thr Met Thr Leu Arg Met Met Arg Asp	
180 185 190	
ttc ggc att gag acc agc acc gac gga gcc acc gtc agc gtc cct cca	624
Phe Gly Ile Glu Thr Ser Thr Asp Gly Ala Thr Val Ser Val Pro Pro	
195 200 205	
ggg cgc tac aca gcc cgg cgg tat gaa ata gaa ccg gat gcg tca act	672
Gly Arg Tyr Thr Ala Arg Arg Tyr Glu Ile Glu Pro Asp Ala Ser Thr	
210 215 220	
gcg tcg tac ttc gcc gcc gct tcc gcc gtc tct ggc agg cgc ttc gaa	720
Ala Ser Tyr Phe Ala Ala Ala Ser Ala Val Ser Gly Arg Arg Phe Glu	
225 230 235 240	

```

ttt caa ggc ctt ggc aca gac agc atc caa ggc gac acg tca ttc ttc 768
Phe Gln Gly Leu Gly Thr Asp Ser Ile Gln Gly Asp Thr Ser Phe Phe
245 250 255

aat gta ctt ggg cgg ctc ggt gcg gag gtc cac tgg gca tcc aac tcg 816
Asn Val Leu Gly Arg Leu Gly Ala Glu Val His Trp Ala Ser Asn Ser
260 265 270

gtc acc ata cgg gga ccg gaa agg ctg acc ggc gac att gaa gtg gat 864
Val Thr Ile Arg Gly Pro Glu Arg Leu Thr Gly Asp Ile Glu Val Asp
275 280 285

atg ggc gag att tcg gac acc ttc atg aca ctc gcg gcg att gcc cct 912
Met Gly Glu Ile Ser Asp Thr Phe Met Thr Leu Ala Ala Ile Ala Pro
290 295 300

ttg gcc gat gga ccc atc acg ata acc aac att ggt cat gca cgg ttg 960
Leu Ala Asp Gly Pro Ile Thr Ile Thr Asn Ile Gly His Ala Arg Leu
305 310 315

aag gaa tcc gac cgc atc tca gcg atg gaa agc aac ctg cgc acg ctc 1008
Lys Glu Ser Asp Arg Ile Ser Ala Met Glu Ser Asn Leu Arg Thr Leu
325 330 335

ggt gta caa acc gac gtc gga cac gac tgg atg aga atc tac ccc tct 1056
Gly Val Gln Thr Asp Val Gly His Asp Trp Met Arg Ile Tyr Pro Ser
340 345 350

acc ccg cac ggc ggt aga gtg aat tgc cac cgg gac cac agg atc gct 1104
Thr Pro His Gly Gly Arg Val Asn Cys His Arg Asp His Arg Ile Ala
355 360 365

atg gcg ttt tca atc ctg gga ctg aga gtg gac ggg att acc ctc gac 1152
Met Ala Phe Ser Ile Leu Gly Leu Arg Val Asp Gly Ile Thr Leu Asp
370 375 380

gac cct caa tgc gtc ggg aag acc ttt cct ggc ttc ttc gac tac ctt 1200
Asp Pro Gln Cys Val Gly Lys Thr Phe Pro Gly Phe Phe Asp Tyr Leu
385 390 395 400

gga cgc ctt ttc ccc gaa aag gcg ctt acg ctc ccc ggc tag 1242
Gly Arg Leu Phe Pro Glu Lys Ala Leu Thr Leu Pro Gly *
405 410

```

```

ggg 1244

```

```

<210> 35
<211> 413
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> GRG23(ace3) variant sequence (GRG23(ace3) I174V)

```

```

<400> 35
Met Glu Thr Asp Arg Leu Val Ile Pro Gly Ser Lys Ser Ile Thr Asn
1 5 10 15
Arg Ala Leu Leu Leu Ala Ala Ala Lys Gly Thr Ser Val Leu Val
20 25 30
Arg Pro Leu Val Ser Ala Asp Thr Ser Ala Phe Lys Thr Ala Ile Gln
35 40 45
Ala Leu Gly Ala Asn Val Ser Ala Asp Gly Asp Asp Trp Val Val Glu
50 55 60

```

Gly	Leu	Gly	Gln	Ala	Pro	Asn	Leu	Asp	Ala	Asp	Ile	Trp	Cys	Glu	Asp
65					70				75						80
Ala	Gly	Thr	Val	Ala	Arg	Phe	Leu	Pro	Pro	Phe	Val	Ala	Ala	Gly	Gln
				85					90					95	
Gly	Lys	Phe	Thr	Val	Asp	Gly	Ser	Glu	Gln	Leu	Arg	Arg	Arg	Pro	Leu
			100					105						110	
Arg	Pro	Val	Val	Asp	Gly	Ile	Arg	His	Leu	Gly	Ala	Arg	Val	Ser	Ser
		115					120					125			
Glu	Gln	Leu	Pro	Leu	Thr	Ile	Glu	Ala	Ser	Gly	Leu	Ala	Gly	Gly	Glu
	130					135					140				
Tyr	Glu	Ile	Glu	Ala	His	Gln	Ser	Ser	Gln	Phe	Ala	Ser	Gly	Leu	Ile
145					150					155					160
Met	Ala	Ala	Pro	Tyr	Ala	Arg	Gln	Gly	Leu	Arg	Val	Arg	Val	Pro	Asn
			165					170						175	
Pro	Val	Ser	Gln	Pro	Tyr	Leu	Thr	Met	Thr	Leu	Arg	Met	Met	Arg	Asp
			180					185					190		
Phe	Gly	Ile	Glu	Thr	Ser	Thr	Asp	Gly	Ala	Thr	Val	Ser	Val	Pro	Pro
		195					200					205			
Gly	Arg	Tyr	Thr	Ala	Arg	Arg	Tyr	Glu	Ile	Glu	Pro	Asp	Ala	Ser	Thr
	210					215					220				
Ala	Ser	Tyr	Phe	Ala	Ala	Ala	Ser	Ala	Val	Ser	Gly	Arg	Arg	Phe	Glu
225					230					235					240
Phe	Gln	Gly	Leu	Gly	Thr	Asp	Ser	Ile	Gln	Gly	Asp	Thr	Ser	Phe	Phe
			245						250					255	
Asn	Val	Leu	Gly	Arg	Leu	Gly	Ala	Glu	Val	His	Trp	Ala	Ser	Asn	Ser
		260						265					270		
Val	Thr	Ile	Arg	Gly	Pro	Glu	Arg	Leu	Thr	Gly	Asp	Ile	Glu	Val	Asp
		275					280					285			
Met	Gly	Glu	Ile	Ser	Asp	Thr	Phe	Met	Thr	Leu	Ala	Ala	Ile	Ala	Pro
	290				295						300				
Leu	Ala	Asp	Gly	Pro	Ile	Thr	Ile	Thr	Asn	Ile	Gly	His	Ala	Arg	Leu
305					310					315					320
Lys	Glu	Ser	Asp	Arg	Ile	Ser	Ala	Met	Glu	Ser	Asn	Leu	Arg	Thr	Leu
			325						330					335	
Gly	Val	Gln	Thr	Asp	Val	Gly	His	Asp	Trp	Met	Arg	Ile	Tyr	Pro	Ser
			340					345					350		
Thr	Pro	His	Gly	Gly	Arg	Val	Asn	Cys	His	Arg	Asp	His	Arg	Ile	Ala
		355					360					365			
Met	Ala	Phe	Ser	Ile	Leu	Gly	Leu	Arg	Val	Asp	Gly	Ile	Thr	Leu	Asp
	370					375					380				
Asp	Pro	Gln	Cys	Val	Gly	Lys	Thr	Phe	Pro	Gly	Phe	Phe	Asp	Tyr	Leu
385					390					395					400
Gly	Arg	Leu	Phe	Pro	Glu	Lys	Ala	Leu	Thr	Leu	Pro	Gly			
			405						410						

53645-19

CLAIMS:

1. An isolated or recombinant nucleic acid molecule selected from the group consisting of:
 - a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34; and,
 - b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35.
2. The isolated or recombinant nucleic acid molecule of claim 1, wherein said nucleotide sequence is a synthetic sequence that has been designed for expression in a plant.
3. The isolated or recombinant nucleic acid molecule of claim 1, wherein said nucleotide sequence is operably linked to a promoter capable of directing expression of a coding sequence in a plant cell.
4. A vector comprising the nucleic acid molecule of claim 1, 2, or 3.
5. The vector of claim 4, further comprising a nucleic acid molecule encoding a heterologous polypeptide.
6. A bacterial host cell comprising the nucleic acid molecule of claim 1, 2, or 3.
7. A plant host cell comprising the nucleic acid molecule of claim 1, 2, or 3.
8. A method for obtaining a transformed plant cell, characterized in that it comprises:
 - a) transforming a plant cell with the vector of claim 4;
 - b) culturing said plant cell under plant cell growing conditions.
9. A method for obtaining a transgenic plant, characterized in that it comprises the method of claim 8 and further comprises the step of:

53645-19

c) regenerating a transgenic plant.

10. The plant host cell of claim 7, which is from maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, or oilseed rape.

5 11. The plant host cell of claim 7, which is from a soybean plant.

12. The plant host cell of claim 7, which is from a corn plant.

13. The plant host cell of claim 7, which is from a seed.

14. An isolated or recombinant polypeptide selected from the group consisting of:

10 a) a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35; and,

b) a polypeptide encoded by the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34.

15. The polypeptide of claim 14 further comprising a heterologous amino acid sequence.

15 16. A method for producing a polypeptide with herbicide resistance activity, comprising culturing the plant host cell of claim 7 under conditions in which a nucleic acid molecule encoding the polypeptide is expressed, said polypeptide being selected from the group consisting of:

20 a) a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35; and,

b) a polypeptide encoded by the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34.

53645-19

17. A method for conferring resistance to an herbicide in a plant, said method comprising transforming said plant with a DNA construct, said construct comprising a promoter that drives expression in a plant cell operably linked with a nucleotide sequence selected from the group consisting of SEQ ID NO:28, 30, 32, or 34, and regenerating a
5 transformed plant.

18. The method of claim 17, wherein said herbicide is glyphosate.

19. A method for obtaining a transformed plant, characterized in that it comprises the steps of:

a) transforming a plant cell with a DNA construct comprising a nucleotide
10 sequence that encodes a protein having herbicide resistance activity, wherein said nucleotide sequence is selected from the group consisting of:

i) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:28, 30, 32, or 34; and,

ii) a nucleic acid molecule which encodes a polypeptide comprising the amino
15 acid sequence of SEQ ID NO:29, 31, 33, or 35;

wherein said nucleotide sequence is operably linked to a promoter that drives expression of a coding sequence in a plant cell;

b) culturing said plant cell under plant cell growing conditions; and

c) regenerating a transformed plant.

20 20. The method of claim 19, wherein said plant is a soybean plant.

21. The method of claim 19, wherein said plant is a corn plant.

22. The method of claim 19, wherein said plant is selected from the group consisting of maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, and oilseed rape.

53645-19

23. A plant cell having stably incorporated into its genome a DNA construct comprising a nucleotide sequence that encodes a protein having herbicide resistance activity, wherein said nucleotide sequence is selected from the group consisting of:

- 5 a) a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:28, 30, 32 or 34; and,
- b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:29, 31, 33, or 35;

wherein said nucleotide sequence is operably linked to a promoter that drives expression of a coding sequence in a plant cell.

10 24. The plant cell of claim 23, which is from a soybean plant.

25. The plant cell of claim 23, which is from a corn plant.

26. The plant cell of claim 23, which is from maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, or oilseed rape.

15 27. The plant cell of claim 23, which is from a seed.

28. A method for increasing vigor or yield in a plant comprising:

a) providing a plant comprising the nucleotide sequence set forth in SEQ ID NO:28, 30, 32, or 34;

b) contacting said plant with an effective concentration of glyphosate; and,

20 c) growing said plant under conditions wherein the temperature is higher than ambient environmental temperature for at least two consecutive hours per day for at least four days following contact with said glyphosate, wherein said days following contact is within the growing season of the plant,

53645-19

wherein the vigor or yield of said plant is higher than the vigor or yield of a plant expressing a glyphosate tolerance EPSP synthase that does not have a temperature optimum higher than ambient environmental temperature.

29. The method of claim 28, wherein the temperature in step (c) is about 32°C to
5 about 60°C.
30. A method for conferring resistance to glyphosate in a plant comprising:
 - a) providing a plant comprising the nucleotide sequence set forth in SEQ ID NO:28, 30, 32, or 34;
 - b) contacting said plant with an effective concentration of glyphosate; and,
 - 10 c) growing said plant under conditions wherein the temperature is higher than ambient environmental temperature for at least two consecutive hours per day for at least four days following contact with said glyphosate, wherein said days following contact is within the growing season of the plant.
31. The method of claim 30, wherein the temperature in step (c) is about 32°C to
15 about 60°C.
32. The isolated or recombinant nucleic acid molecule of claim 1 comprising the nucleotide sequence of SEQ ID NO:28.
33. The isolated or recombinant nucleic acid molecule of claim 1 comprising the nucleotide sequence of SEQ ID NO:30.
- 20 34. The isolated or recombinant nucleic acid molecule of claim 1 comprising the nucleotide sequence of SEQ ID NO:32.
35. The isolated or recombinant nucleic acid molecule of claim 1 comprising the nucleotide sequence of SEQ ID NO:34.

53645-19

36. The isolated or recombinant nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:29.

37. The isolated or recombinant nucleic acid molecule of claim 1, wherein said
5 nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:31.

38. The isolated or recombinant nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:33.

10 39. The isolated or recombinant nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:35.




Fig 1
1/3




FIG. 2
2/3




FIG. 3
3/3